Details of Disease

General Information of Disease (ID: DISA7HR7)

• Disease Name: Matthew-Wood syndrome
• Synonyms: spear syndrome; pulmonary Hypoplasia-diaphragmatic hernia-anophthalmia-Cardiac defect; microphthalmia, syndromic 9; microphthalmia syndromic 9; pulmonary agenesis, microphthalmia, and diaphragmatic defect; clinical anophthalmia mild facial dysmorphism lung heart and diaphragm malformations; anophthalmia/microphthalmia and pulmonary hypoplasia; Matthew Wood syndrome; microphthalmia, isolated, with coloboma 8; anophthalmia, clinical, with mild Facial Dysmorphism and variable malformations of the lung, heart, and diaphragm; pulmonary agenesis microphthalmi and diaphragmatic defect; MCOPS9; anophthalmia-pulmonary hypoplasia syndrome; syndromic microphthalmia type 9; microphthalmia syndromic type 9; microphthalmia, syndromic type 9; Matthew-Wood syndrome
• Definition: Matthew-Wood syndrome is a rare clinical entity including as main characteristics anophthalmia or severe microphthalmia, and pulmonary hypoplasia or aplasia.
• Disease Hierarchy:
  DISH7BRI: Thoracic malformation
  DISD0WVL: Multiple congenital anomalies/dysmorphic syndrome without intellectual disability
  DISR3JBJ: Syndromic microphthalmia
  DISA7HR7: Matthew-Wood syndrome
• Disease Identifiers:
  MONDO ID: MONDO_0011010
  MESH ID: C537768
  UMLS CUI: C1832661
  OMIM ID: 601186
  MedGen ID: 318679
  Orphanet ID: 2470
  SNOMED CT ID: 722458000

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 264 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AGR2	TT9K86S	Limited	Altered Expression	[1]
ANO1	TTOJI4S	Limited	Biomarker	[2]
BTG1	TTL7N2W	Limited	Altered Expression	[3]
CBX7	TTBN3HC	Limited	Altered Expression	[4]
CCKBR	TTVFO0U	Limited	Biomarker	[5]
CCN1	TTPK79J	Limited	Biomarker	[6]
CCR2	TTFZYTO	Limited	Biomarker	[7]
CD44	TTWFBT7	Limited	Biomarker	[8]
CDH3	TTARMD9	Limited	Biomarker	[9]
CHKA	TT10AWB	Limited	Biomarker	[10]
CTSE	TTLXC4Q	Limited	Altered Expression	[11]
CXCL10	TTQOVYA	Limited	Biomarker	[12]
CXCR2	TT30C9G	Limited	Altered Expression	[13]
DCLK1	TTOHTCY	Limited	Altered Expression	[14]
DKK1	TTE3RAC	Limited	Biomarker	[15]
EIF5A2	TTH53G9	Limited	Altered Expression	[16]
F2RL1	TTQR74A	Limited	Biomarker	[17]
FAM83B	TT1Q347	Limited	Altered Expression	[18]
FGF7	TTFY134	Limited	Biomarker	[19]
FOXC2	TTLBAP1	Limited	Biomarker	[20]
FOXO1	TTLRVIA	Limited	Biomarker	[21]
GPR55	TTNET8J	Limited	Genetic Variation	[22]
GRK3	TT5A4DX	Limited	Altered Expression	[23]
HCRTR1	TT60Q8D	Limited	Altered Expression	[24]
HDAC1	TT6R7JZ	Limited	Biomarker	[25]
IMP3	TTEJA2R	Limited	Biomarker	[26]
ITGB6	TTKQSXZ	Limited	Biomarker	[27]
KLF4	TTTI53X	Limited	Altered Expression	[28]
L1CAM	TTC9D3K	Limited	Altered Expression	[29]
LASP1	TTZJA87	Limited	Altered Expression	[30]
LGALS1	TTO3NYT	Limited	Biomarker	[31]
LGMN	TTPTWV5	Limited	Biomarker	[32]
MAZ	TT059DA	Limited	Altered Expression	[6]
MIA	TT5HNVS	Limited	Biomarker	[33]
MLYCD	TT9Z4YD	Limited	Biomarker	[34]
MUC16	TTC1PS3	Limited	Altered Expression	[35]
NR1I3	TTRANFM	Limited	Biomarker	[36]
NT5E	TTK0O6Y	Limited	Biomarker	[37]
P4HA1	TTNH25W	Limited	Biomarker	[38]
PDCD1	TTNBFWK	Limited	Biomarker	[39]
PDX1	TT8SGZK	Limited	Genetic Variation	[40]
PGD	TTZ3IFB	Limited	Altered Expression	[41]
PKM	TT4LOT8	Limited	Altered Expression	[42]
PLD1	TT3T17P	Limited	Biomarker	[43]
PPM1A	TTLA7IX	Limited	Biomarker	[44]
PRKD1	TTSLUMT	Limited	Biomarker	[45]
PRNP	TTY5F9C	Limited	Biomarker	[46]
RAC1	TT2M9CG	Limited	Biomarker	[47]
RICTOR	TT143WL	Limited	Altered Expression	[48]
SETD2	TTPC3H4	Limited	Biomarker	[49]
SLC8A1	TTCF82X	Limited	Genetic Variation	[50]
SQLE	TTE14XG	Limited	Altered Expression	[51]
STK33	TTP34DQ	Limited	Altered Expression	[52]
TAGLN2	TTP6BIJ	Limited	Altered Expression	[53]
TBK1	TTMP03S	Limited	Altered Expression	[54]
TFF1	TTNOJIZ	Limited	Biomarker	[55]
TK1	TTP3QRF	Limited	Biomarker	[56]
TNFSF4	TTBW580	Limited	Altered Expression	[57]
TPBG	TT70MLA	Limited	Biomarker	[58]
TRPM2	TTEBMN7	Limited	Altered Expression	[59]
BRCA2	TTUARD6	Disputed	Genetic Variation	[60]
EPHB2	TTKPV6O	Disputed	Altered Expression	[61]
GLI1	TTJOMH6	Disputed	Biomarker	[62]
KDM3A	TTKXS4A	Disputed	Altered Expression	[63]
MCOLN1	TT9XBVO	Disputed	Altered Expression	[64]
RARB	TTISP28	Supportive	Autosomal dominant	[65]
ADAM8	TTQWYMD	moderate	Altered Expression	[66]
CCND3	TT1JXNR	moderate	Altered Expression	[67]
CDC25B	TTR0SWN	moderate	Biomarker	[68]
CDK5R1	TTBYM6V	moderate	Genetic Variation	[69]
DEPTOR	TTLYP6D	moderate	Altered Expression	[70]
DPEP1	TTYUENF	moderate	Biomarker	[71]
FABP5	TTNT2S6	moderate	Biomarker	[72]
FGF19	TTGCH11	moderate	Biomarker	[73]
IL12A	TTRTK6Y	moderate	Genetic Variation	[69]
KLK6	TTLPF4X	moderate	Altered Expression	[74]
ROR2	TTUDPCI	moderate	Biomarker	[75]
RPL15	TTQRVC9	moderate	Altered Expression	[76]
SENP1	TTW9HY5	moderate	Biomarker	[77]
ABCG1	TTMWDGU	Strong	Biomarker	[78]
ABCG2	TTIMJ02	Strong	Altered Expression	[79]
ABL2	TT1A6HL	Strong	Biomarker	[80]
ADAM9	TTTYQNS	Strong	Altered Expression	[81]
ALOX5AP	TTDMBF5	Strong	Biomarker	[82]
ANXA10	TT0NL6U	Strong	Biomarker	[83]
ANXA2	TT4YANI	Strong	Biomarker	[84]
AQP3	TTLDNMQ	Strong	Altered Expression	[85]
ATF3	TTCE793	Strong	Biomarker	[86]
AZGP1	TTUPYLV	Strong	Altered Expression	[87]
BIRC7	TTHZ8TA	Strong	Altered Expression	[88]
CA9	TT2LVK8	Strong	Altered Expression	[89]
CALCRL	TTY6O0Q	Strong	Altered Expression	[90]
CAPN1	TT1WBIJ	Strong	Altered Expression	[91]
CAPN2	TTG5QB7	Strong	Altered Expression	[91]
CBL	TT7QT13	Strong	Biomarker	[92]
CCR9	TTIPS8B	Strong	Altered Expression	[93]
CD24	TTCTYNP	Strong	Biomarker	[83]
CD276	TT6CQUM	Strong	Biomarker	[94]
CD47	TT28S46	Strong	Altered Expression	[95]
CD9	TTZEIBV	Strong	Genetic Variation	[96]
CDC25A	TTLZS4Q	Strong	Altered Expression	[97]
CDC25C	TTESBNC	Strong	Altered Expression	[98]
CDK7	TTQYF7G	Strong	Biomarker	[99]
CEACAM5	TTY6DTE	Strong	Biomarker	[100]
CEBPA	TT5LWG1	Strong	Biomarker	[101]
CEL	TTTRNQW	Strong	Biomarker	[102]
CERK	TT9XRNV	Strong	Biomarker	[103]
CHRNA7	TTLA931	Strong	Altered Expression	[104]
CHST15	TTFK7E1	Strong	Biomarker	[105]
CHUK	TT1F8OQ	Strong	Genetic Variation	[106]
CLDN4	TTMTS9H	Strong	Biomarker	[107]
CPB1	TT4UJX5	Strong	Altered Expression	[108]
CTRC	TT3RMNA	Strong	Biomarker	[109]
DEK	TT1NMGV	Strong	Altered Expression	[110]
DSG3	TTEO4P8	Strong	Altered Expression	[111]
DYRK1A	TTSBVFO	Strong	Biomarker	[112]
EIF4EBP1	TTKGEBL	Strong	Altered Expression	[113]
EPCAM	TTZ8WH4	Strong	Biomarker	[114]
EREG	TTYSB89	Strong	Altered Expression	[115]
EZR	TTE47YC	Strong	Biomarker	[116]
FBXO3	TTUX14L	Strong	Genetic Variation	[117]
FCGRT	TTKLPHO	Strong	Genetic Variation	[118]
FDPS	TTIKWV4	Strong	Biomarker	[119]
FER	TTRA9G0	Strong	Altered Expression	[120]
FES	TTLBY21	Strong	Biomarker	[119]
FGF10	TTNPEFX	Strong	Genetic Variation	[121]
FUT3	TTUPAD7	Strong	Genetic Variation	[122]
FYN	TT2B9KF	Strong	Biomarker	[123]
GABRP	TT3E0DI	Strong	Altered Expression	[124]
GAP43	TTSGLN5	Strong	Biomarker	[125]
GOT1	TTU507L	Strong	Biomarker	[126]
GRB2	TTEYRJ9	Strong	Biomarker	[127]
GRHL2	TTUGH4C	Strong	Biomarker	[128]
HDAC5	TTUELN5	Strong	Biomarker	[129]
HHAT	TT1VNCG	Strong	Biomarker	[130]
HMGA2	TTSTVM0	Strong	Altered Expression	[131]
HNF1A	TT01M3K	Strong	Biomarker	[132]
HNRNPA2B1	TT8UPW6	Strong	Altered Expression	[133]
HSPE1	TTWYMFE	Strong	Altered Expression	[134]
HTATIP2	TTC6IX5	Strong	Altered Expression	[135]
ID1	TTBXVDE	Strong	Altered Expression	[136]
IGFBP2	TTU4QSN	Strong	Altered Expression	[137]
IL1R2	TT51DEV	Strong	Biomarker	[138]
IL21R	TTZO9B0	Strong	Altered Expression	[139]
INPP5D	TTTP2Z1	Strong	Biomarker	[140]
ISG15	TTVOH3T	Strong	Biomarker	[141]
ITGA1	TTPERWV	Strong	Biomarker	[142]
ITGA11	TTANXZ7	Strong	Altered Expression	[143]
KCNN4	TT7M9I6	Strong	Biomarker	[124]
KRT17	TTKV0EC	Strong	Altered Expression	[144]
LAMB3	TT2WOUQ	Strong	Biomarker	[145]
LAMP1	TTC214J	Strong	Biomarker	[146]
LILRB1	TTC0QRJ	Strong	Biomarker	[147]
LIPE	TTLUQ8E	Strong	Biomarker	[148]
LONP1	TTM1VPZ	Strong	Biomarker	[149]
LOXL2	TTFSUHX	Strong	Biomarker	[150]
MAGEA3	TTWSKHD	Strong	Altered Expression	[151]
MAP3K10	TT9FN4J	Strong	Biomarker	[152]
MAP3K20	TTTUZ3O	Strong	Biomarker	[153]
MAP4K4	TT6NI13	Strong	Altered Expression	[154]
MAPKAPK2	TTMUG9D	Strong	Biomarker	[155]
MAPKAPK3	TTFS4VU	Strong	Biomarker	[156]
MKNK1	TTEZAUX	Strong	Biomarker	[157]
MKNK2	TTRECN3	Strong	Posttranslational Modification	[158]
MMP10	TTXLEG7	Strong	Altered Expression	[159]
MMP14	TTJ4QE7	Strong	Biomarker	[160]
MSI2	TTTXQF6	Strong	Biomarker	[28]
MUC17	TTVO0JU	Strong	Biomarker	[161]
MUC5AC	TTEL90S	Strong	Biomarker	[162]
NEDD4	TT1QU6G	Strong	Biomarker	[163]
NEDD8	TTNDC4K	Strong	Genetic Variation	[164]
NELL1	TT7H4BF	Strong	Altered Expression	[165]
NES	TTHZ752	Strong	Altered Expression	[166]
NTF3	TTZHKV9	Strong	Biomarker	[167]
NTSR1	TTTUMEP	Strong	Posttranslational Modification	[168]
OSMR	TTAH0KM	Strong	Biomarker	[169]
P2RY4	TT24DGP	Strong	Altered Expression	[170]
PAK2	TT279WO	Strong	Posttranslational Modification	[171]
PARG	TT39J16	Strong	Biomarker	[172]
PBK	TTMY6BZ	Strong	Biomarker	[173]
PDE8A	TTIS4OW	Strong	Biomarker	[174]
PECAM1	TT4EZB2	Strong	Biomarker	[175]
PIN1	TTJNTSI	Strong	Altered Expression	[176]
PKN1	TTSL41O	Strong	Genetic Variation	[177]
PLAUR	TTNOSTX	Strong	Biomarker	[178]
PRKACA	TT5U49F	Strong	Genetic Variation	[179]
PRMT1	TTVOJAI	Strong	Altered Expression	[180]
PYY	TTVFJLX	Strong	Biomarker	[181]
RACK1	TTJ10AL	Strong	Biomarker	[182]
RARB	TTISP28	Strong	GermlineCausalMutation	[65]
RBP4	TT0C8BY	Strong	Altered Expression	[183]
RIPK2	TTCQ2E5	Strong	Biomarker	[184]
RNF43	TTD91BL	Strong	Genetic Variation	[185]
ROBO4	TT3S9TY	Strong	Biomarker	[186]
ROCK2	TTGWKQJ	Strong	Biomarker	[187]
RRM1	TTWP0NS	Strong	Biomarker	[188]
RRM2	TT1S4LJ	Strong	Altered Expression	[113]
SAA1	TTY0DN9	Strong	Biomarker	[189]
SDC2	TT5H2F0	Strong	Biomarker	[190]
SEMA4D	TT5UT28	Strong	Altered Expression	[191]
SERPINB5	TT1KW50	Strong	Biomarker	[192]
SFRP4	TTX8I1Y	Strong	Altered Expression	[193]
SLC29A1	TTLXAKE	Strong	Biomarker	[194]
SLC6A14	TTB6H2S	Strong	Biomarker	[195]
SMYD2	TT7YJFO	Strong	Biomarker	[156]
SPOCK1	TTF23RE	Strong	Altered Expression	[196]
SSTR2	TTZ6T9E	Strong	Biomarker	[197]
TIAM1	TTNU6I5	Strong	Altered Expression	[198]
TNC	TTUCPMY	Strong	Altered Expression	[199]
TNFRSF10A	TT5WLRX	Strong	Biomarker	[200]
TNFRSF10B	TTW20TU	Strong	Biomarker	[201]
TRPC3	TTNVC34	Strong	Altered Expression	[202]
UCP1	TTI12YJ	Strong	Altered Expression	[203]
USP44	TTJLTNM	Strong	Biomarker	[204]
USP5	TTGYTMA	Strong	Altered Expression	[205]
VEGFD	TTOM5H4	Strong	Biomarker	[206]
VTCN1	TTCK85E	Strong	Altered Expression	[207]
WDR5	TT7OFWB	Strong	Biomarker	[208]
WEE1	TTJFOAL	Strong	Altered Expression	[209]
WWP2	TT6TU05	Strong	Biomarker	[210]
XPO1	TTCJUR4	Strong	Altered Expression	[211]
XRCC5	TTCB9KW	Strong	Altered Expression	[212]
YAP1	TT8UN2D	Strong	Biomarker	[213]
AREG	TT76B3W	Definitive	Altered Expression	[214]
ASPH	TT2KHP7	Definitive	Biomarker	[215]
BBC3	TT7JUKC	Definitive	Biomarker	[216]
BCAT2	TTF9OQ6	Definitive	Biomarker	[217]
BUB1	TT78309	Definitive	Altered Expression	[218]
C1QBP	TTWTD7F	Definitive	Altered Expression	[219]
CDC20	TTBKFDV	Definitive	Altered Expression	[220]
CMA1	TT8VUE0	Definitive	Altered Expression	[221]
DCK	TTJOCE4	Definitive	Biomarker	[222]
DDR1	TTI1FPZ	Definitive	Biomarker	[223]
DKK2	TTST5KX	Definitive	Altered Expression	[224]
DLL4	TTV23LH	Definitive	Altered Expression	[225]
EIF5A	TTIVCNR	Definitive	Altered Expression	[226]
EPHA4	TTG84D3	Definitive	Altered Expression	[227]
FOSL1	TTY8LZG	Definitive	Altered Expression	[228]
FSCN1	TTTRS9B	Definitive	Altered Expression	[229]
FUT4	TTNV1KZ	Definitive	Biomarker	[230]
HK2	TTK02H8	Definitive	Biomarker	[231]
IDO2	TTALN9W	Definitive	Biomarker	[232]
IDUA	TT0IUKX	Definitive	Altered Expression	[233]
IKBKB	TTJ3E9X	Definitive	Biomarker	[234]
IRAK4	TTILUKB	Definitive	Biomarker	[235]
ITGB1	TTBVIQC	Definitive	Biomarker	[236]
JAG2	TTOJY1B	Definitive	Genetic Variation	[237]
KRT19	TT3JF9E	Definitive	Altered Expression	[238]
LAPTM4B	TTEJQT0	Definitive	Biomarker	[239]
MTDH	TTH6SA5	Definitive	Biomarker	[240]
NOTCH3	TTVX7IA	Definitive	Altered Expression	[241]
NRP1	TTIPJCB	Definitive	Biomarker	[242]
PAK4	TT7Y3BZ	Definitive	Altered Expression	[243]
PDPK1	TTYMGWX	Definitive	Biomarker	[244]
PIM3	TTCGOIN	Definitive	Biomarker	[245]
PPP3CA	TTA4LDE	Definitive	Biomarker	[246]
PRSS1	TT2WR1T	Definitive	Genetic Variation	[247]
REG4	TTVZEHU	Definitive	Altered Expression	[248]
S100A6	TT716MY	Definitive	Altered Expression	[129]
SCN10A	TT90XZ8	Definitive	Biomarker	[215]
SLC16A1	TTN1J82	Definitive	Altered Expression	[221]
SLC16A3	TTG6VD5	Definitive	Altered Expression	[249]
TTK	TTP7EGM	Definitive	Altered Expression	[233]
VSIR	TT51SK8	Definitive	Altered Expression	[250]

This Disease Is Related to 6 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC22A17	DTXI9E6	Limited	Biomarker	[251]
ATP2B1	DTJWQ1L	Strong	Biomarker	[42]
KCNK2	DTENHUP	Strong	Biomarker	[252]
SLC28A1	DT0EQPW	Strong	Biomarker	[253]
SLC28A3	DT4YL5R	Strong	Altered Expression	[254]
SLC35F6	DTJ7R5M	Strong	Biomarker	[255]

This Disease Is Related to 11 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ALDH1A1	DE2JP1Y	Limited	Altered Expression	[256]
AKR1B10	DEP6GT1	moderate	Biomarker	[257]
CES2	DETHCPD	Strong	Biomarker	[258]
CYB5A	DE9A2LB	Strong	Altered Expression	[259]
FAAH	DEUM1EX	Strong	Biomarker	[260]
HK1	DEDMAGE	Strong	Biomarker	[261]
HPGD	DEHKSC6	Strong	Genetic Variation	[256]
PGPEP1	DEVDR46	Strong	Altered Expression	[117]
PON2	DEHJU7E	Strong	Biomarker	[216]
PRODH	DEVJIHS	Strong	Biomarker	[262]
TPMT	DEFQ8VO	Strong	Altered Expression	[263]

This Disease Is Related to 374 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AHNAK	OT6KH1WG	Limited	Biomarker	[264]
ARHGEF15	OTGHDJFP	Limited	Altered Expression	[265]
ARR3	OTRZ00CH	Limited	Biomarker	[36]
ASS1	OT4ZMG0Q	Limited	Altered Expression	[266]
BAG3	OTVXYUDQ	Limited	Biomarker	[267]
BTF3	OT5ZZFJL	Limited	Altered Expression	[268]
CADM4	OT0TFMFE	Limited	Altered Expression	[269]
CCDC68	OT4KF6TL	Limited	Altered Expression	[270]
CCNG1	OT17IA9L	Limited	Biomarker	[271]
CDH15	OTJ1TO02	Limited	Biomarker	[9]
CNN2	OTH3CSXA	Limited	Altered Expression	[272]
COMMD7	OTWWJ97D	Limited	Altered Expression	[273]
COPS6	OTG9AAG0	Limited	Altered Expression	[274]
CRKL	OTOYSD1R	Limited	Altered Expression	[275]
CST7	OTQWZUVQ	Limited	Altered Expression	[276]
CSTA	OT1K68KE	Limited	Biomarker	[277]
CUZD1	OTDQJVZ8	Limited	Altered Expression	[51]
CXADR	OT9ZP02A	Limited	Biomarker	[36]
CYRIB	OTLRN4L1	Limited	Biomarker	[278]
DCX	OTISR7K3	Limited	Altered Expression	[279]
DNER	OT2GH2E5	Limited	Biomarker	[212]
DTNBP1	OT9UQT2S	Limited	Biomarker	[280]
DUSP2	OTH54FMR	Limited	Biomarker	[281]
EFNB2	OT0DCUOM	Limited	Biomarker	[282]
EI24	OTD4NOYS	Limited	Biomarker	[283]
EIF4G1	OT2CF1E6	Limited	Altered Expression	[284]
ENO1	OTB1KWJS	Limited	Altered Expression	[285]
EYA4	OTINGR3Z	Limited	Altered Expression	[286]
FEZF1	OTRX4NOT	Limited	Biomarker	[287]
FLOT2	OTZ0QR5L	Limited	Biomarker	[288]
FZD5	OTXFFY56	Limited	Biomarker	[185]
GAB2	OTBFN705	Limited	Biomarker	[275]
GNAI2	OTTLGRGH	Limited	Biomarker	[289]
GOLM1	OTOZSV6O	Limited	Altered Expression	[290]
GPC5	OT8NR7GC	Limited	Altered Expression	[291]
HAS2	OTTD3PAL	Limited	Biomarker	[292]
HMGN5	OTUUAHVQ	Limited	Biomarker	[293]
HOXB7	OTC7WYU8	Limited	Biomarker	[294]
HSPA14	OTZCA5LK	Limited	Biomarker	[295]
IFIT3	OTPGHZB9	Limited	Biomarker	[296]
IGF2BP3	OTB97VIK	Limited	Biomarker	[297]
IMMP2L	OT9WGAFD	Limited	Biomarker	[298]
IQGAP1	OTZRWTGA	Limited	Biomarker	[299]
KLF10	OT4F4UGS	Limited	Biomarker	[300]
KLF9	OTBFEJRQ	Limited	Altered Expression	[301]
LAT	OTZC1XZ1	Limited	Biomarker	[302]
LRG1	OTLD0KWA	Limited	Altered Expression	[303]
LTBP2	OTS88GSD	Limited	Altered Expression	[304]
LUM	OTSRC874	Limited	Biomarker	[305]
MAP4K5	OTUFGLXE	Limited	Altered Expression	[258]
MCM2	OTGGORIQ	Limited	Altered Expression	[306]
MDC1	OTEUQH4J	Limited	Biomarker	[307]
MMRN1	OT7ZNYHT	Limited	Altered Expression	[308]
MMUT	OTBBBV70	Limited	Biomarker	[306]
MUC13	OTWKS9MF	Limited	Altered Expression	[309]
MUCL3	OTGAD3I0	Limited	Biomarker	[310]
MYBL2	OTZ3JX8Q	Limited	Altered Expression	[311]
NECTIN1	OTTE5ZR6	Limited	Altered Expression	[312]
NEU2	OTW76T35	Limited	Altered Expression	[313]
NUDT1	OTZSES3W	Limited	Altered Expression	[314]
NUPR1	OT4FU8C0	Limited	Biomarker	[315]
OCIAD1	OTJBY7PV	Limited	Altered Expression	[316]
PAFAH1B2	OTRDWN2V	Limited	Biomarker	[317]
PCBP2	OTXCN9CG	Limited	Altered Expression	[318]
PCDH10	OT2GIT0E	Limited	Posttranslational Modification	[319]
PCDHAC2	OTNFJS0M	Limited	Posttranslational Modification	[319]
PDHX	OTG7O271	Limited	Genetic Variation	[40]
PEAK1	OTVVM637	Limited	Biomarker	[320]
PF4V1	OT2CXM6L	Limited	Altered Expression	[321]
PGAM1	OTZ5DB06	Limited	Biomarker	[322]
PHLPP1	OTIFXW8D	Limited	Biomarker	[323]
PIGR	OT6GLSUL	Limited	Altered Expression	[324]
PITPNM3	OTHLZY8D	Limited	Biomarker	[325]
PLP1	OT8CM9CX	Limited	Genetic Variation	[326]
REG1A	OTMHUH1D	Limited	Biomarker	[327]
REG3G	OTLIUY8Z	Limited	Biomarker	[328]
RO60	OTLGM5A8	Limited	Altered Expression	[329]
S100A11	OTI57KDN	Limited	Altered Expression	[330]
SAV1	OTSAEV92	Limited	Altered Expression	[331]
SDS	OT5WTJ2M	Limited	Biomarker	[332]
SEMA3C	OTEGUY7F	Limited	Altered Expression	[333]
SERP1	OT60XXUP	Limited	Altered Expression	[334]
SKAP2	OTSF44KP	Limited	Altered Expression	[335]
SOX9	OTVDJFGN	Limited	Altered Expression	[336]
SPPL3	OT2HLJF6	Limited	Biomarker	[298]
TAS2R10	OT4RWZZD	Limited	Biomarker	[337]
TFAP2C	OTUDIW05	Limited	Biomarker	[338]
TGFBR3	OTQOOUC4	Limited	Biomarker	[339]
TRIM13	OTQIUACB	Limited	Biomarker	[36]
ASH2L	OT3HG324	Disputed	Biomarker	[340]
GIPC1	OTXLVCPJ	Disputed	Biomarker	[341]
THAP9	OTY4TSJO	Disputed	Altered Expression	[342]
RARB	OT367U3E	Supportive	Autosomal dominant	[65]
ADAM15	OTZ7VLTP	moderate	Biomarker	[343]
ATP6V0D1	OT9GU2NW	moderate	Altered Expression	[69]
CD151	OTF3UZS7	moderate	Biomarker	[344]
CDCA5	OTZLCQ5U	moderate	Genetic Variation	[69]
CDK5R2	OTNUTLPU	moderate	Altered Expression	[69]
CLIC3	OT5KUZ3A	moderate	Biomarker	[345]
ESRP1	OTNCS4SL	moderate	Biomarker	[346]
FCN2	OTTHJBKZ	moderate	Genetic Variation	[69]
FOXL1	OT89XFPN	moderate	Altered Expression	[347]
FRAT1	OT1PS84E	moderate	Altered Expression	[348]
GCHFR	OTEOT8GI	moderate	Genetic Variation	[69]
GOLPH3	OTDLGYM3	moderate	Altered Expression	[349]
HOXC8	OTJUYU8J	moderate	Altered Expression	[350]
ILF2	OTWWVM9X	moderate	Altered Expression	[351]
MNAT1	OTXLOYCB	moderate	Genetic Variation	[69]
NMU	OTW9X7BQ	moderate	Biomarker	[352]
PA2G4	OT7IG7HT	moderate	Altered Expression	[353]
PLCD1	OT6WFVXZ	moderate	Altered Expression	[354]
PLCD3	OTB22A4J	moderate	Biomarker	[354]
PNKD	OT6G9UXN	moderate	Altered Expression	[355]
PODXL	OTPNQXF3	moderate	Altered Expression	[356]
RALGDS	OTG36NI7	moderate	Genetic Variation	[357]
RASSF6	OT25GVWY	moderate	Biomarker	[358]
RMC1	OT7K8MTJ	moderate	Biomarker	[359]
RNF2	OTFPLOIN	moderate	Altered Expression	[360]
TBX4	OTW58FG4	moderate	Altered Expression	[361]
TM4SF1	OTY0ECQN	moderate	Biomarker	[362]
TRAF2	OT1MEZZN	moderate	Altered Expression	[363]
TTLL4	OTHEIBQG	moderate	Biomarker	[364]
ACVR1C	OTOTYERF	Strong	Biomarker	[365]
ACYP2	OTRB4S6X	Strong	Genetic Variation	[366]
ADAM12	OTZKOTDB	Strong	Altered Expression	[367]
AIMP1	OTTA5C3U	Strong	Biomarker	[368]
ALDH7A1	OTV57BZD	Strong	Biomarker	[142]
ANTXR1	OT5W1GPC	Strong	Biomarker	[369]
AP1S3	OTPCMV24	Strong	Biomarker	[370]
ARSH	OTG0X9UQ	Strong	Biomarker	[127]
ASPM	OTKXQMNA	Strong	Altered Expression	[371]
ATG4D	OTSWUO4R	Strong	Biomarker	[372]
ATL2	OT93AUOO	Strong	Biomarker	[210]
ATP2B2	OT1NPZ9T	Strong	Biomarker	[42]
ATP2B3	OT9DIEOP	Strong	Biomarker	[42]
BCL9L	OTTWI90E	Strong	Altered Expression	[373]
BHLHA15	OTY7IER8	Strong	Altered Expression	[374]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[375]
BNIP3L	OTJKOMXE	Strong	Biomarker	[376]
BPIFA2	OTLFSDZD	Strong	Genetic Variation	[377]
BTN3A2	OT3DIBU3	Strong	Biomarker	[378]
BTN3A3	OTKMSJRA	Strong	Altered Expression	[378]
BTNL9	OT3PWOH6	Strong	Altered Expression	[378]
C16orf74	OTLLVHH0	Strong	Biomarker	[379]
C1GALT1	OT2ZSZ6P	Strong	Altered Expression	[380]
C1GALT1C1	OTRTZUF5	Strong	Altered Expression	[381]
C6orf58	OTT2T3DU	Strong	Biomarker	[382]
CAPN3	OTCHG3YK	Strong	Altered Expression	[91]
CCAR2	OTLUDG5T	Strong	Altered Expression	[383]
CCL18	OT7JYSK9	Strong	Biomarker	[325]
CCL7	OTDIS99H	Strong	Biomarker	[384]
CCL8	OTCTWYN8	Strong	Altered Expression	[385]
CD101	OT4QX6BR	Strong	Biomarker	[386]
CD177	OTS79FNF	Strong	Altered Expression	[387]
CD63	OT2UGZA9	Strong	Biomarker	[388]
CDC6	OTX93FE7	Strong	Altered Expression	[113]
CDH10	OTK3D5WP	Strong	Biomarker	[389]
CDH17	OT9EV2XK	Strong	Biomarker	[390]
CDK14	OT385ZH1	Strong	Biomarker	[391]
CDKN2D	OT2TTZPZ	Strong	Altered Expression	[392]
CDO1	OTLG1P77	Strong	Posttranslational Modification	[393]
CDX2	OTCG4TSY	Strong	Altered Expression	[394]
CEMIP	OTK80FYN	Strong	Biomarker	[395]
CETN1	OTGQ8JOZ	Strong	Biomarker	[396]
CHGB	OT7SAQT2	Strong	Biomarker	[397]
CILK1	OTWOYEYP	Strong	Biomarker	[153]
CKAP4	OTDUC9ME	Strong	Biomarker	[398]
CLSTN3	OTPUFK4C	Strong	Biomarker	[399]
CRABP2	OTY01V9G	Strong	Biomarker	[400]
CRLF3	OTT9TMXN	Strong	Genetic Variation	[401]
CSDE1	OT15D7GH	Strong	Altered Expression	[170]
CTSZ	OTSCX2LL	Strong	Altered Expression	[402]
DAB2	OTRMQTMZ	Strong	Altered Expression	[403]
DDX3X	OTDO4TRX	Strong	Altered Expression	[404]
DEFA1	OT5N1B9B	Strong	Altered Expression	[405]
DHX9	OT5AAOQI	Strong	Biomarker	[406]
DLG5	OTU9Z17K	Strong	Biomarker	[407]
DMKN	OTRIGZMK	Strong	Biomarker	[408]
DOK2	OTIJ38UF	Strong	Genetic Variation	[177]
DSG2	OTJPB2TO	Strong	Biomarker	[111]
ECM1	OT1K65VW	Strong	Biomarker	[409]
EDIL3	OTDVVNS0	Strong	Altered Expression	[410]
EIF4A1	OTMTBX6N	Strong	Biomarker	[113]
EIF4A2	OT08H03R	Strong	Biomarker	[113]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[123]
EMC3	OTY2H39E	Strong	Biomarker	[411]
EML1	OTOP2E01	Strong	Biomarker	[368]
ENDOD1	OTME0ZW5	Strong	Altered Expression	[370]
EPS8	OTZ6ES6V	Strong	Biomarker	[412]
FBP1	OTQBANEP	Strong	Biomarker	[204]
FEN1	OT6QGG7O	Strong	Biomarker	[413]
FHL2	OT0OAYWT	Strong	Altered Expression	[414]
FOXA2	OTJOCVOY	Strong	Biomarker	[415]
FOXP2	OTVX6A59	Strong	Biomarker	[416]
FXYD3	OT9PPRHE	Strong	Biomarker	[417]
FZD1	OTZATHVS	Strong	Biomarker	[89]
GALNT3	OT7M67WT	Strong	Biomarker	[418]
GBP1	OTUM7RPJ	Strong	Biomarker	[419]
GCA	OTAJ7ZHG	Strong	Altered Expression	[420]
GDE1	OTU6FSBF	Strong	Altered Expression	[209]
GFI1	OT9HB9H8	Strong	Altered Expression	[421]
GLUD1	OTXKOCUH	Strong	Biomarker	[422]
GNMT	OT0O2OQO	Strong	Posttranslational Modification	[423]
GOT2	OT6XBWN0	Strong	Altered Expression	[424]
GP2	OTB6TMGY	Strong	Biomarker	[425]
GPRC5A	OTPOCWR7	Strong	Biomarker	[426]
HAT1	OT307KEN	Strong	Altered Expression	[427]
HCLS1	OTX7WGYN	Strong	Biomarker	[428]
HEATR1	OTOWIB9Z	Strong	Biomarker	[429]
HGD	OTTKLQOO	Strong	Biomarker	[430]
HMMR	OT4M0JTZ	Strong	Biomarker	[431]
HNRNPK	OTNPRM8U	Strong	Altered Expression	[432]
HNRNPU	OTLQN1E2	Strong	Biomarker	[433]
HOXB9	OTMVHQOU	Strong	Biomarker	[434]
HRNR	OT560QR5	Strong	Biomarker	[435]
IER3	OTZJI5FZ	Strong	Altered Expression	[436]
IGF2BP2	OT4ZSEEE	Strong	Biomarker	[437]
IKBKE	OT5VYOSM	Strong	Biomarker	[438]
IRF9	OTK4MYQJ	Strong	Genetic Variation	[401]
ITGA3	OTBCH21D	Strong	Biomarker	[439]
ITIH5	OTP46PZM	Strong	Altered Expression	[440]
KCNJ16	OT174UPV	Strong	Altered Expression	[441]
KCNK1	OTBXPTKX	Strong	Biomarker	[441]
KDM2B	OTDMCVW7	Strong	Biomarker	[442]
KHSRP	OTDHZARB	Strong	Biomarker	[428]
KIF20A	OTXOQHE0	Strong	Altered Expression	[407]
KIF21A	OT511XD9	Strong	Biomarker	[443]
KLHL1	OTAX6SAD	Strong	Biomarker	[253]
KRT16	OTGA0EQN	Strong	Altered Expression	[444]
KRT81	OTMKIK2S	Strong	Biomarker	[445]
LAMA3	OTFME7HT	Strong	Biomarker	[446]
LDHB	OT9B1CT3	Strong	Altered Expression	[447]
LEMD2	OT0YLT7L	Strong	Biomarker	[448]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[449]
LPCAT2	OT6NTBAA	Strong	Biomarker	[370]
MAP6	OTPUI00F	Strong	Genetic Variation	[450]
MCIDAS	OTK1JVAH	Strong	Biomarker	[451]
MDH1	OTJEO4E8	Strong	Biomarker	[452]
ME2	OTO4LL76	Strong	Biomarker	[453]
MEIS1	OTH9DKAD	Strong	Biomarker	[454]
MEPE	OTXJRUW0	Strong	Biomarker	[455]
MIA2	OTOGTUTU	Strong	Genetic Variation	[456]
MSX2	OT1WDKE1	Strong	Altered Expression	[457]
MTSS1	OT5DTDO2	Strong	Altered Expression	[458]
MUC20	OTYYE1GK	Strong	Altered Expression	[459]
MYOZ3	OTRN16R4	Strong	Biomarker	[399]
MZB1	OT071TET	Strong	Biomarker	[460]
NADK	OTYN9GX0	Strong	Biomarker	[461]
NAE1	OTMC6F3Y	Strong	Genetic Variation	[164]
NAF1	OTMJKJAK	Strong	Genetic Variation	[366]
NECTIN2	OTIE0W6O	Strong	Altered Expression	[404]
NFAT5	OTKIE59S	Strong	Altered Expression	[462]
NLN	OTFRITPU	Strong	Biomarker	[117]
NOP14	OTKPM0Z5	Strong	Biomarker	[463]
NOSTRIN	OT0LDSGS	Strong	Biomarker	[464]
NSG2	OTJ0NSPL	Strong	Altered Expression	[465]
NTS	OTPGDNQS	Strong	Biomarker	[168]
NUP160	OTUKVV3I	Strong	Biomarker	[433]
OGA	OT7ZBWT1	Strong	Biomarker	[466]
OGT	OT1Z1ZXE	Strong	Biomarker	[466]
ONECUT1	OTK1QUQT	Strong	Biomarker	[467]
OPN4	OT1LZ7TS	Strong	Biomarker	[117]
PACC1	OTKBS8CC	Strong	Biomarker	[468]
PAF1	OTDDGUBQ	Strong	Altered Expression	[228]
PALD1	OTLGUM8H	Strong	Biomarker	[469]
PALLD	OTZ2MUJZ	Strong	Biomarker	[469]
PARPBP	OTPZDGW7	Strong	Biomarker	[470]
PCDH1	OT7KDEL3	Strong	Biomarker	[390]
PFN1	OTHTGA1H	Strong	Altered Expression	[471]
PHLDA2	OTMV9DPP	Strong	Biomarker	[370]
PKHD1	OTAH8SMF	Strong	Biomarker	[472]
PLAC8	OT3SYRUJ	Strong	Biomarker	[473]
PLEC	OTU4XDEG	Strong	Biomarker	[474]
PMAIP1	OTXEE550	Strong	Biomarker	[475]
POLR2D	OTW7RZ18	Strong	Altered Expression	[183]
PPP2R2A	OT9297OG	Strong	Genetic Variation	[476]
PPP4C	OT4B0TNV	Strong	Altered Expression	[477]
PRAG1	OTV83SGI	Strong	Altered Expression	[478]
PRDM14	OTWZKY4L	Strong	Altered Expression	[479]
PRKACB	OT6RMDCE	Strong	Genetic Variation	[179]
PRSS2	OTOMVUWL	Strong	Genetic Variation	[247]
PSMA6	OTJ6RPX5	Strong	Biomarker	[480]
PSPH	OTV1PVAX	Strong	Genetic Variation	[377]
PSPN	OT54LLZJ	Strong	Genetic Variation	[377]
PTF1A	OT7SWA57	Strong	Genetic Variation	[401]
QSOX1	OT4ZPK4P	Strong	Biomarker	[481]
RAB23	OTBAKFBR	Strong	Biomarker	[482]
RAB31	OTMLXQZ0	Strong	Altered Expression	[483]
RAB5A	OTFR2KM4	Strong	Biomarker	[372]
RACGAP1	OTQE8IEH	Strong	Biomarker	[484]
RASGRF1	OTNWJ7EN	Strong	Altered Expression	[98]
REG1B	OTSC2133	Strong	Altered Expression	[485]
RERE	OT3G4GBZ	Strong	Biomarker	[80]
RGL2	OTJCW5ZD	Strong	Biomarker	[486]
RIDA	OTW4098I	Strong	Genetic Variation	[377]
RITA1	OTUH8IPS	Strong	Biomarker	[487]
ROBO2	OTFJ9FQW	Strong	Altered Expression	[488]
RTL10	OTHGB81W	Strong	Altered Expression	[475]
SCG2	OTXWUQQL	Strong	Altered Expression	[125]
SCTR	OTC80IMR	Strong	Biomarker	[489]
SEC11C	OTP3WS0U	Strong	Altered Expression	[490]
SEMG1	OT6Z4BPQ	Strong	Biomarker	[397]
SERPINB7	OTZ95LR2	Strong	Biomarker	[491]
SFXN1	OTL66767	Strong	Biomarker	[492]
SIGLEC7	OTNDLURR	Strong	Biomarker	[428]
SIN3B	OTFB59FK	Strong	Biomarker	[493]
SLURP1	OT89YD2E	Strong	Biomarker	[104]
SMAD2	OTC6VB4K	Strong	Biomarker	[494]
SMDT1	OTDBR8D1	Strong	Altered Expression	[495]
SPARCL1	OT74DWMV	Strong	Altered Expression	[496]
SPRY2	OTH0CRCZ	Strong	Biomarker	[497]
ST13	OTNML6UP	Strong	Genetic Variation	[401]
ST6GAL1	OT7US3NO	Strong	Biomarker	[498]
STN1	OT8UWRA3	Strong	Genetic Variation	[366]
STXBP3	OTTTYMAQ	Strong	Genetic Variation	[377]
SUFU	OT0IRYG1	Strong	Biomarker	[499]
SYCE1L	OTXU44F3	Strong	Biomarker	[253]
SYP	OTFJKMO4	Strong	Biomarker	[238]
TAPBP	OTL81AVZ	Strong	Biomarker	[500]
TCF7	OT1ID822	Strong	Biomarker	[501]
TGFBI	OTR443C5	Strong	Biomarker	[502]
TGIF1	OTN9VHAG	Strong	Altered Expression	[292]
THBS2	OTXET551	Strong	Biomarker	[503]
THY1	OTVONVTB	Strong	Altered Expression	[504]
TM4SF18	OTDES2NC	Strong	Biomarker	[505]
TMPRSS4	OTCCGY2K	Strong	Biomarker	[506]
TNS3	OTPG2D8Z	Strong	Genetic Variation	[507]
TRIM29	OT2DNESG	Strong	Altered Expression	[155]
ADCY3	OTGOQM6B	Definitive	Biomarker	[412]
AHNAK2	OTD2X4BX	Definitive	Altered Expression	[508]
ARHGEF10	OTHJ1Y4I	Definitive	Biomarker	[509]
CDC42	OT5QBC5M	Definitive	Altered Expression	[236]
CUX1	OTU1LCNJ	Definitive	Altered Expression	[510]
ECT2	OTQDUCT6	Definitive	Biomarker	[506]
EHF	OTY6TPWD	Definitive	Biomarker	[511]
FASTKD2	OTD635WX	Definitive	Biomarker	[512]
FERMT2	OTZNPWWX	Definitive	Altered Expression	[513]
GGPS1	OTVEHG28	Definitive	Biomarker	[514]
GPR68	OT1NXSMN	Definitive	Biomarker	[515]
HHLA2	OTYBTVQS	Definitive	Altered Expression	[250]
KAT2A	OTN0W2SW	Definitive	Altered Expression	[516]
KLK10	OTD573EL	Definitive	Biomarker	[517]
LAMTOR5	OTER0U8L	Definitive	Altered Expression	[518]
LGALS4	OTKQCG0H	Definitive	Biomarker	[390]
LIMS1	OT729S0T	Definitive	Altered Expression	[519]
LIN28B	OTVWP0FN	Definitive	Biomarker	[520]
MAP2K4	OTZPZX11	Definitive	Altered Expression	[521]
MCAT	OTH07FIW	Definitive	Altered Expression	[221]
MCTS1	OT7SAOJP	Definitive	Altered Expression	[221]
MINDY4	OTBZ2SZB	Definitive	Altered Expression	[85]
MPEG1	OT7DAO0F	Definitive	Altered Expression	[233]
MPP7	OT3G3HTZ	Definitive	Biomarker	[452]
MSH3	OTD3YPVL	Definitive	Altered Expression	[522]
MTA2	OTCCYIQJ	Definitive	Altered Expression	[523]
MUC4	OTLT11V1	Definitive	Altered Expression	[524]
MYOF	OTRFC3IJ	Definitive	Biomarker	[525]
NFATC1	OT4TMERS	Definitive	Altered Expression	[526]
NT5C1A	OTS7UF36	Definitive	Altered Expression	[527]
PALB2	OT6DNDBG	Definitive	Genetic Variation	[528]
PER2	OTU2B1DJ	Definitive	Biomarker	[529]
PGK1	OT6V1ICH	Definitive	Altered Expression	[530]
PLIN2	OTRXJ9UN	Definitive	Biomarker	[531]
POLE	OTFM3MMU	Definitive	Altered Expression	[532]
PRELP	OT9EEBUJ	Definitive	Biomarker	[533]
PRRX1	OTTZK5G8	Definitive	Biomarker	[534]
RPS27	OTFXKY7P	Definitive	Altered Expression	[233]
S100PBP	OT6O7Y14	Definitive	Altered Expression	[402]
SERPINB2	OT72QLZB	Definitive	Altered Expression	[535]
SLC16A4	OT1YXBKC	Definitive	Altered Expression	[249]
SRPX2	OT6A63TX	Definitive	Altered Expression	[483]
STRA6	OT2IDF27	Definitive	Autosomal recessive	[536]
TEAD1	OTK6971C	Definitive	Biomarker	[537]
TFPI2	OTZCRWOR	Definitive	Biomarker	[537]
TMPO	OTL68EL4	Definitive	Altered Expression	[538]

References

• [1] ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation.Oncogene. 2017 Jun 1;36(22):3094-3103. doi: 10.1038/onc.2016.459. Epub 2016 Dec 12.
• [2] ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC).Pflugers Arch. 2015 Jul;467(7):1495-1508. doi: 10.1007/s00424-014-1598-8. Epub 2014 Aug 28.
• [3] BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis.Int J Biol Markers. 2018 May;33(2):189-194. doi: 10.5301/ijbm.5000310. Epub 2017 Oct 25.
• [4] CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.Oncotarget. 2017 Jan 31;8(5):8010-8021. doi: 10.18632/oncotarget.14037.
• [5] Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.Mol Carcinog. 2019 Oct;58(10):1908-1918. doi: 10.1002/mc.23084. Epub 2019 Jul 16.
• [6] The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.J Biol Chem. 2018 Mar 23;293(12):4334-4349. doi: 10.1074/jbc.RA117.000333. Epub 2018 Feb 6.
• [7] Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.Invest New Drugs. 2020 Jun;38(3):800-811. doi: 10.1007/s10637-019-00830-3. Epub 2019 Jul 12.
• [8] CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.In Vivo. 2018 Nov-Dec;32(6):1533-1540. doi: 10.21873/invivo.11411.
• [9] Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma.Br J Cancer. 2018 Feb 20;118(4):546-557. doi: 10.1038/bjc.2017.411. Epub 2017 Nov 21.
• [10] Choline Kinase Alpha (CHK) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.Mol Cancer Ther. 2016 Feb;15(2):323-33. doi: 10.1158/1535-7163.MCT-15-0214. Epub 2016 Jan 14.
• [11] Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer.Pancreatology. 2019 Oct;19(7):951-956. doi: 10.1016/j.pan.2019.09.009. Epub 2019 Sep 20.
• [12] Plasma IFN--inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma.Pancreatology. 2019 Mar;19(2):340-345. doi: 10.1016/j.pan.2019.01.015. Epub 2019 Jan 19.
• [13] Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients.Front Immunol. 2019 Apr 9;10:496. doi: 10.3389/fimmu.2019.00496. eCollection 2019.
• [14] Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.J Oncol. 2019 Aug 5;2019:6402925. doi: 10.1155/2019/6402925. eCollection 2019.
• [15] Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.Clin Chim Acta. 2019 Jan;488:226-234. doi: 10.1016/j.cca.2018.11.023. Epub 2018 Nov 16.
• [16] N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.Exp Ther Med. 2017 Sep;14(3):2101-2107. doi: 10.3892/etm.2017.4740. Epub 2017 Jul 9.
• [17] Transforming Growth Factor-1/Activin Receptor-like Kinase 5-Mediated Cell Migration is Dependent on the Protein Proteinase-Activated Receptor 2 but not on Proteinase-Activated Receptor 2-Stimulated G(q)-Calcium Signaling.Mol Pharmacol. 2017 Nov;92(5):519-532. doi: 10.1124/mol.117.109017. Epub 2017 Aug 25.
• [18] High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation.J Cancer. 2017 Sep 12;8(16):3154-3165. doi: 10.7150/jca.20086. eCollection 2017.
• [19] Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer.Am J Pathol. 2007 Jun;170(6):1964-74. doi: 10.2353/ajpath.2007.060935.
• [20] FOXC2 is up-regulated in pancreatic ductal adenocarcinoma and promotes the growth and migration of cancer cells.Tumour Biol. 2016 Jul;37(7):8579-85. doi: 10.1007/s13277-015-4607-4. Epub 2016 Jan 6.
• [21] MiR-27a-regulated FOXO1 promotes pancreatic ductal adenocarcinoma cell progression by enhancing Wnt/-catenin signaling activity.Am J Transl Res. 2019 May 15;11(5):3069-3080. eCollection 2019.
• [22] GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.Oncogene. 2018 Dec;37(49):6368-6382. doi: 10.1038/s41388-018-0390-1. Epub 2018 Jul 30.
• [23] High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2018 Feb;214(2):228-232. doi: 10.1016/j.prp.2017.11.013. Epub 2017 Nov 20.
• [24] In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.Oncotarget. 2018 Jan 9;9(6):6952-6967. doi: 10.18632/oncotarget.24084. eCollection 2018 Jan 23.
• [25] Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy.Cancers (Basel). 2019 Sep 7;11(9):1327. doi: 10.3390/cancers11091327.
• [26] The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion.BMC Cancer. 2015 Apr 11;15:266. doi: 10.1186/s12885-015-1251-8.
• [27] Integrin 6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).Tumour Biol. 2016 Apr;37(4):5117-31. doi: 10.1007/s13277-015-4353-7. Epub 2015 Nov 7.
• [28] The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.Clin Cancer Res. 2017 Feb 1;23(3):687-696. doi: 10.1158/1078-0432.CCR-16-1064. Epub 2016 Jul 22.
• [29] L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression.Oncogene. 2019 Jan;38(4):596-608. doi: 10.1038/s41388-018-0458-y. Epub 2018 Aug 31.
• [30] LASP1 is a HIF1 target gene critical for metastasis of pancreatic cancer.Cancer Res. 2015 Jan 1;75(1):111-9. doi: 10.1158/0008-5472.CAN-14-2040. Epub 2014 Nov 10.
• [31] PSC-derived Galectin-1 inducing epithelial-mesenchymal transition of pancreatic ductal adenocarcinoma cells by activating the NF-B pathway.Oncotarget. 2017 Sep 23;8(49):86488-86502. doi: 10.18632/oncotarget.21212. eCollection 2017 Oct 17.
• [32] Asparaginyl endopeptidase enhances pancreatic ductal adenocarcinoma cell invasion in an exosome-dependent manner and correlates with poor prognosis.Int J Oncol. 2018 May;52(5):1651-1660. doi: 10.3892/ijo.2018.4318. Epub 2018 Mar 15.
• [33] Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.J Virol. 2020 Jan 17;94(3):e01643-19. doi: 10.1128/JVI.01643-19. Print 2020 Jan 17.
• [34] The density of mast cells c-Kit(+) and tryptase(+) correlates with each other and with angiogenesis in pancreatic cancer patients.Oncotarget. 2017 Jul 31;8(41):70463-70471. doi: 10.18632/oncotarget.19716. eCollection 2017 Sep 19.
• [35] The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.Pancreas. 2018 Nov/Dec;47(10):1290-1295. doi: 10.1097/MPA.0000000000001181.
• [36] Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.Gut. 2019 Jun;68(6):1052-1064. doi: 10.1136/gutjnl-2018-316595. Epub 2018 Aug 18.
• [37] The distinct role of CD73 in the progression of pancreatic cancer.J Mol Med (Berl). 2019 Jun;97(6):803-815. doi: 10.1007/s00109-018-01742-0. Epub 2019 Mar 29.
• [38] P4HA1/HIF1 feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.Biochem Biophys Res Commun. 2019 Aug 27;516(3):606-612. doi: 10.1016/j.bbrc.2019.06.096. Epub 2019 Jun 22.
• [39] A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.J Immunother Cancer. 2019 Aug 29;7(1):233. doi: 10.1186/s40425-019-0703-0.
• [40] Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer.Acta Diabetol. 2019 Sep;56(9):1013-1022. doi: 10.1007/s00592-019-01335-4. Epub 2019 Apr 15.
• [41] Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases.Oncogene. 2018 Sep;37(38):5248-5256. doi: 10.1038/s41388-018-0346-5. Epub 2018 May 30.
• [42] Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2).Br J Cancer. 2020 Jan;122(2):266-278. doi: 10.1038/s41416-019-0675-3. Epub 2019 Dec 10.
• [43] Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients.Oncotarget. 2016 Nov 29;7(48):78557-78565. doi: 10.18632/oncotarget.12447.
• [44] Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.Hum Pathol. 2016 Sep;55:151-8. doi: 10.1016/j.humpath.2016.05.002. Epub 2016 May 16.
• [45] Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.Mol Cancer Res. 2017 Jul;15(7):929-941. doi: 10.1158/1541-7786.MCR-17-0023. Epub 2017 Mar 30.
• [46] Prion Protein Family Contributes to Tumorigenesis via Multiple Pathways.Adv Exp Med Biol. 2017;1018:207-224. doi: 10.1007/978-981-10-5765-6_13.
• [47] Negative Control of Cell Migration by Rac1b in Highly Metastatic Pancreatic Cancer Cells Is Mediated by Sequential Induction of Nonactivated Smad3 and Biglycan.Cancers (Basel). 2019 Dec 6;11(12):1959. doi: 10.3390/cancers11121959.
• [48] Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.Oncotarget. 2017 Apr 11;8(15):24491-24505. doi: 10.18632/oncotarget.15524.
• [49] Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.Gut. 2020 Apr;69(4):715-726. doi: 10.1136/gutjnl-2019-318362. Epub 2019 Jul 11.
• [50] Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.Theranostics. 2018 May 23;8(12):3366-3379. doi: 10.7150/thno.23978. eCollection 2018.
• [51] hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.Br J Cancer. 2015 Mar 17;112(6):1076-87. doi: 10.1038/bjc.2015.28.
• [52] STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1.Cancer Res. 2017 Dec 15;77(24):6851-6862. doi: 10.1158/0008-5472.CAN-17-0067. Epub 2017 Oct 16.
• [53] Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer. J Exp Clin Cancer Res. 2018 Jul 24;37(1):166.
• [54] Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.Invest New Drugs. 2019 Feb;37(1):159-165. doi: 10.1007/s10637-018-0650-5. Epub 2018 Jul 30.
• [55] Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer.Pancreatology. 2017 Sep-Oct;17(5):782-787. doi: 10.1016/j.pan.2017.07.188. Epub 2017 Jul 26.
• [56] Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis.Cell Prolif. 2018 Jun;51(3):e12428. doi: 10.1111/cpr.12428. Epub 2017 Dec 20.
• [57] Thymic stromal lymphopoietin in human pancreatic ductal adenocarcinoma: expression and prognostic significance.Oncotarget. 2018 Aug 28;9(67):32795-32809. doi: 10.18632/oncotarget.25997. eCollection 2018 Aug 28.
• [58] Trophoblast glycoprotein promotes pancreatic ductal adenocarcinoma cell metastasis through Wnt/planar cell polarity signaling.Mol Med Rep. 2015 Jul;12(1):503-9. doi: 10.3892/mmr.2015.3412. Epub 2015 Mar 4.
• [59] TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma.Mol Med Rep. 2018 Jun;17(6):7537-7544. doi: 10.3892/mmr.2018.8816. Epub 2018 Mar 28.
• [60] Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.Int J Cancer. 2019 Aug 1;145(3):686-693. doi: 10.1002/ijc.32127. Epub 2019 Feb 7.
• [61] TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.Autophagy. 2020 Mar;16(3):486-500. doi: 10.1080/15548627.2019.1628540. Epub 2019 Jun 17.
• [62] Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.Cancer Res. 2016 Dec 1;76(23):7049-7058. doi: 10.1158/0008-5472.CAN-16-0715. Epub 2016 Oct 6.
• [63] The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.Gastroenterology. 2019 Dec;157(6):1646-1659.e11. doi: 10.1053/j.gastro.2019.08.018. Epub 2019 Aug 20.
• [64] MCOLN1 Promotes Proliferation and Predicts Poor Survival of Patients with Pancreatic Ductal Adenocarcinoma.Dis Markers. 2019 Aug 5;2019:9436047. doi: 10.1155/2019/9436047. eCollection 2019.
• [65] Recessive and dominant mutations in retinoic acid receptor beta in cases with microphthalmia and diaphragmatic hernia. Am J Hum Genet. 2013 Oct 3;93(4):765-72. doi: 10.1016/j.ajhg.2013.08.014. Epub 2013 Sep 26.
• [66] ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.J Cell Mol Med. 2007 Sep-Oct;11(5):1162-74. doi: 10.1111/j.1582-4934.2007.00082.x.
• [67] Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma.Mol Cancer. 2010 Feb 1;9:24. doi: 10.1186/1476-4598-9-24.
• [68] MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.Lab Invest. 2011 Oct;91(10):1472-9. doi: 10.1038/labinvest.2011.99. Epub 2011 Jun 27.
• [69] Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.Clin Cancer Res. 2011 Oct 1;17(19):6140-50. doi: 10.1158/1078-0432.CCR-10-2288. Epub 2011 Aug 8.
• [70] DEPTOR has growth suppression activity against pancreatic cancer cells.Oncotarget. 2014 Dec 30;5(24):12811-9. doi: 10.18632/oncotarget.2659.
• [71] DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20.
• [72] Molecular determinants of retinoic acid sensitivity in pancreatic cancer.Clin Cancer Res. 2012 Jan 1;18(1):280-9. doi: 10.1158/1078-0432.CCR-11-2165. Epub 2011 Oct 18.
• [73] Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.Int J Oncol. 2011 Jan;38(1):133-43.
• [74] Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma.Br J Cancer. 2008 Nov 4;99(9):1484-92. doi: 10.1038/sj.bjc.6604717. Epub 2008 Oct 14.
• [75] High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma.Sci Rep. 2015 Aug 11;5:12991. doi: 10.1038/srep12991.
• [76] Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.Oncotarget. 2015 Nov 10;6(35):37028-42. doi: 10.18632/oncotarget.5939.
• [77] SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9.Tumour Biol. 2014 Dec;35(12):12729-35. doi: 10.1007/s13277-014-2598-1. Epub 2014 Sep 13.
• [78] Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues.Pancreas. 2013 May;42(4):707-16. doi: 10.1097/MPA.0b013e318279b861.
• [79] An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma.PLoS One. 2019 Oct 17;14(10):e0223554. doi: 10.1371/journal.pone.0223554. eCollection 2019.
• [80] Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.Neoplasia. 2011 Nov;13(11):1026-34. doi: 10.1593/neo.111016.
• [81] ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.Mol Oncol. 2019 Feb;13(2):456-479. doi: 10.1002/1878-0261.12426. Epub 2019 Jan 9.
• [82] Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.Carcinogenesis. 2013 Jun;34(6):1251-9. doi: 10.1093/carcin/bgt053. Epub 2013 Feb 7.
• [83] Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.PLoS One. 2017 Apr 3;12(4):e0175039. doi: 10.1371/journal.pone.0175039. eCollection 2017.
• [84] Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.J Immunother Cancer. 2019 May 22;7(1):132. doi: 10.1186/s40425-019-0601-5.
• [85] AQP1 and AQP3 Expression are Associated With Severe Symptoms and Poor-prognosis of the Pancreatic Ductal Adenocarcinoma.Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):40-47. doi: 10.1097/PAI.0000000000000523.
• [86] The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant Zip2.Oncogene. 2019 Feb;38(9):1461-1476. doi: 10.1038/s41388-018-0518-3. Epub 2018 Oct 9.
• [87] Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer.Arch Physiol Biochem. 2011 May;117(2):78-87. doi: 10.3109/13813455.2011.560609.
• [88] BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance.Cancer Biomark. 2016;17(4):437-444. doi: 10.3233/CBM-160660.
• [89] Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.Pathol Oncol Res. 2018 Oct;24(4):899-906. doi: 10.1007/s12253-017-0284-5. Epub 2017 Sep 18.
• [90] Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion.Int J Cancer. 2007 Jul 1;121(1):21-32. doi: 10.1002/ijc.22596.
• [91] Expression of three calpain isoform genes in human skeletal muscles.J Neurol Sci. 1998 Mar 5;155(2):163-9. doi: 10.1016/s0022-510x(97)00309-2.
• [92] Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.Clin Cancer Res. 2015 Jan 1;21(1):157-65. doi: 10.1158/1078-0432.CCR-14-0610. Epub 2014 Oct 27.
• [93] Clinical significance and prospective molecular mechanism of CC motif chemokine receptors in patients with earlystage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.Oncol Rep. 2019 Nov;42(5):1856-1868. doi: 10.3892/or.2019.7277. Epub 2019 Aug 13.
• [94] B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma.Int J Biochem Cell Biol. 2019 Mar;108:84-91. doi: 10.1016/j.biocel.2019.01.011. Epub 2019 Jan 18.
• [95] Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.J Hematol Oncol. 2019 Nov 27;12(1):124. doi: 10.1186/s13045-019-0822-6.
• [96] MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.PLoS One. 2015 Nov 25;10(11):e0143755. doi: 10.1371/journal.pone.0143755. eCollection 2015.
• [97] Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells.Cancer Res. 2007 May 1;67(9):4149-56. doi: 10.1158/0008-5472.CAN-06-4484.
• [98] Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.Oncogene. 2004 Jan 8;23(1):71-81. doi: 10.1038/sj.onc.1206926.
• [99] THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.Oncogene. 2019 May;38(20):3932-3945. doi: 10.1038/s41388-019-0701-1. Epub 2019 Jan 28.
• [100] Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.Cancer Biomark. 2018 Feb 14;21(3):505-511. doi: 10.3233/CBM-170203.
• [101] Targeted Delivery of C/EBP-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC.Mol Ther Nucleic Acids. 2019 Dec 6;18:142-154. doi: 10.1016/j.omtn.2019.08.017. Epub 2019 Aug 22.
• [102] The mucinous domain of pancreatic carboxyl-ester lipase (CEL) contains core 1/core 2 O-glycans that can be modified by ABO blood group determinants.J Biol Chem. 2018 Dec 14;293(50):19476-19491. doi: 10.1074/jbc.RA118.001934. Epub 2018 Oct 12.
• [103] Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility.Biochem Pharmacol. 2018 Oct;156:458-466. doi: 10.1016/j.bcp.2018.09.017. Epub 2018 Sep 15.
• [104] Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer.Oncotarget. 2018 Jan 24;9(14):11734-11751. doi: 10.18632/oncotarget.24312. eCollection 2018 Feb 20.
• [105] Inhibition of Cell Proliferation and Growth of Pancreatic Cancer by Silencing of Carbohydrate Sulfotransferase 15 In Vitro and in a Xenograft Model. PLoS One. 2015 Dec 7;10(12):e0142981.
• [106] miRNA-1290 Promotes Aggressiveness in Pancreatic Ductal Adenocarcinoma by Targeting IKK1.Cell Physiol Biochem. 2018;51(2):711-728. doi: 10.1159/000495328. Epub 2018 Nov 21.
• [107] Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.Mol Cancer Res. 2019 Jan;17(1):70-83. doi: 10.1158/1541-7786.MCR-18-0531. Epub 2018 Aug 31.
• [108] Label-Free Quantitative Proteomics Unravels Carboxypeptidases as the Novel Biomarker in Pancreatic Ductal Adenocarcinoma.Transl Oncol. 2018 Jun;11(3):691-699. doi: 10.1016/j.tranon.2018.03.005. Epub 2018 Apr 6.
• [109] Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.Ann Oncol. 2019 Nov 1;30(Suppl_8):viii36-viii40. doi: 10.1093/annonc/mdz385. Epub 2019 Dec 24.
• [110] Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis.J Cancer. 2019 Jan 29;10(4):911-917. doi: 10.7150/jca.27405. eCollection 2019.
• [111] Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma.Br J Cancer. 2015 Nov 17;113(10):1460-6. doi: 10.1038/bjc.2015.362. Epub 2015 Oct 15.
• [112] Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A. Chem Biol Interact. 2020 Jan 25;316:108913. doi: 10.1016/j.cbi.2019.108913. Epub 2019 Dec 12.
• [113] eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer.JCI Insight. 2019 Nov 1;4(21):e121951. doi: 10.1172/jci.insight.121951.
• [114] Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.Theranostics. 2019 Feb 20;9(5):1417-1425. doi: 10.7150/thno.28745. eCollection 2019.
• [115] Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth.Biochem Biophys Res Commun. 2000 Jul 14;273(3):1019-24. doi: 10.1006/bbrc.2000.3033.
• [116] Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma.Mol Cancer Res. 2019 Apr;17(4):929-936. doi: 10.1158/1541-7786.MCR-18-0367. Epub 2019 Jan 17.
• [117] Glucose metabolic phenotype of pancreatic cancer.World J Gastroenterol. 2016 Mar 28;22(12):3471-85. doi: 10.3748/wjg.v22.i12.3471.
• [118] KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.J Control Release. 2019 Feb 28;296:40-53. doi: 10.1016/j.jconrel.2019.01.014. Epub 2019 Jan 15.
• [119] RAGE maintains high levels of NFB and oncogenic Kras activity in pancreatic cancer.Biochem Biophys Res Commun. 2017 Nov 4;493(1):592-597. doi: 10.1016/j.bbrc.2017.08.147. Epub 2017 Sep 1.
• [120] YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway.Cancer Lett. 2019 Oct 28;463:37-49. doi: 10.1016/j.canlet.2019.07.019. Epub 2019 Aug 9.
• [121] Matthew-Wood syndrome: report of two new cases supporting autosomal recessive inheritance and exclusion of FGF10 and FGFR2.Am J Med Genet A. 2007 Feb 1;143A(3):219-28. doi: 10.1002/ajmg.a.31599.
• [122] Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.Clin Gastroenterol Hepatol. 2020 May;18(5):1161-1169.e5. doi: 10.1016/j.cgh.2019.10.036. Epub 2019 Oct 30.
• [123] Construction of a circRNA-miRNA-mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma.J Cell Biochem. 2020 Jan;121(1):394-406. doi: 10.1002/jcb.29194. Epub 2019 Jun 24.
• [124] GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner.Gut. 2019 Nov;68(11):1994-2006. doi: 10.1136/gutjnl-2018-317479. Epub 2019 Mar 2.
• [125] Perineural invasion in pancreatic cancer: proteomic analysis and invitro modelling.Mol Oncol. 2019 May;13(5):1075-1091. doi: 10.1002/1878-0261.12463. Epub 2019 Mar 5.
• [126] Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism.Cell Commun Signal. 2019 Aug 30;17(1):111. doi: 10.1186/s12964-019-0425-4.
• [127] Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science.J Gastroenterol. 2019 Mar;54(3):218-225. doi: 10.1007/s00535-018-01542-w. Epub 2019 Jan 14.
• [128] Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. Cancer Med. 2017 Nov;6(11):2686-2696.
• [129] Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.Mol Med Rep. 2019 Aug;20(2):1901-1914. doi: 10.3892/mmr.2019.10414. Epub 2019 Jun 24.
• [130] Attenuation of hedgehog acyltransferase-catalyzed sonic Hedgehog palmitoylation causes reduced signaling, proliferation and invasiveness of human carcinoma cells.PLoS One. 2014 Mar 7;9(3):e89899. doi: 10.1371/journal.pone.0089899. eCollection 2014.
• [131] Association of radiomic imaging features and gene expression profile as prognostic factors in pancreatic ductal adenocarcinoma.Am J Transl Res. 2019 Jul 15;11(7):4491-4499. eCollection 2019.
• [132] CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids.Stem Cells Int. 2019 May 2;2019:1024614. doi: 10.1155/2019/1024614. eCollection 2019.
• [133] Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.Gastroenterology. 2014 Oct;147(4):882-892.e8. doi: 10.1053/j.gastro.2014.06.041. Epub 2014 Jul 3.
• [134] Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics.Onco Targets Ther. 2018 Jun 6;11:3345-3357. doi: 10.2147/OTT.S162470. eCollection 2018.
• [135] Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.Int J Cancer. 2014 Mar 15;134(6):1369-78. doi: 10.1002/ijc.28471. Epub 2013 Oct 3.
• [136] The roles of ID-1 in human pancreatic ductal adenocarcinoma and the therapeutic effects of 2-methoxyestradiol.Carcinogenesis. 2018 May 3;39(5):728-737. doi: 10.1093/carcin/bgy035.
• [137] Serum Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 2 as a Novel Biomarker in the Detection of Pancreatic Adenocarcinoma.J Clin Gastroenterol. 2020 Oct;54(9):e83-e88. doi: 10.1097/MCG.0000000000001297.
• [138] Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis.PLoS One. 2010 Aug 19;5(8):e12243. doi: 10.1371/journal.pone.0012243.
• [139] Interleukin 21 Receptor/Ligand Interaction Is Linked to Disease Progression in Pancreatic Cancer.Cells. 2019 Sep 18;8(9):1104. doi: 10.3390/cells8091104.
• [140] A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer.Cancer Lett. 2018 Apr 1;418:75-83. doi: 10.1016/j.canlet.2018.01.007. Epub 2018 Jan 6.
• [141] ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.Cancer Immunol Immunother. 2019 Dec;68(12):2029-2039. doi: 10.1007/s00262-019-02422-9. Epub 2019 Nov 11.
• [142] ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.Sci Rep. 2017 Aug 30;7(1):10060. doi: 10.1038/s41598-017-09946-z.
• [143] Integrin 11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer.FASEB J. 2019 May;33(5):6609-6621. doi: 10.1096/fj.201802336R. Epub 2019 Feb 26.
• [144] Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.Sci Rep. 2019 Aug 2;9(1):11239. doi: 10.1038/s41598-019-47519-4.
• [145] LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.Cell Death Dis. 2019 Mar 8;10(3):230. doi: 10.1038/s41419-019-1320-z.
• [146] UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.J Exp Clin Cancer Res. 2019 Jul 9;38(1):297. doi: 10.1186/s13046-019-1278-9.
• [147] Circular RNA ciRS-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway.Hepatobiliary Pancreat Dis Int. 2019 Dec;18(6):580-586. doi: 10.1016/j.hbpd.2019.03.003. Epub 2019 Mar 9.
• [148] Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice.BMC Cancer. 2018 Aug 7;18(1):797. doi: 10.1186/s12885-018-4713-y.
• [149] Inhibition of LONP1 protects against erastin-induced ferroptosis in Pancreatic ductal adenocarcinoma PANC1 cells.Biochem Biophys Res Commun. 2020 Feb 19;522(4):1063-1068. doi: 10.1016/j.bbrc.2019.11.187. Epub 2019 Dec 9.
• [150] miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.Mol Cancer Res. 2020 Feb;18(2):311-323. doi: 10.1158/1541-7786.MCR-19-0594. Epub 2019 Oct 29.
• [151] The clinical significance of MAGEA3 expression in pancreatic cancer.Int J Cancer. 2006 May 1;118(9):2269-75. doi: 10.1002/ijc.21656.
• [152] MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.Cancer Lett. 2013 Feb 28;329(2):228-35. doi: 10.1016/j.canlet.2012.11.005. Epub 2012 Nov 23.
• [153] The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.Mol Cancer Ther. 2012 Sep;11(9):1999-2009. doi: 10.1158/1535-7163.MCT-12-0017. Epub 2012 Jul 2.
• [154] Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.J Exp Clin Cancer Res. 2018 Jul 3;37(1):130. doi: 10.1186/s13046-018-0807-2.
• [155] ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.Cancer Res. 2014 Mar 15;74(6):1778-88. doi: 10.1158/0008-5472.CAN-13-2289. Epub 2014 Jan 27.
• [156] Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.Genes Dev. 2016 Apr 1;30(7):772-85. doi: 10.1101/gad.275529.115. Epub 2016 Mar 17.
• [157] Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice.Oncotarget. 2016 Dec 24;8(32):52381-52402. doi: 10.18632/oncotarget.14154. eCollection 2017 Aug 8.
• [158] Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.Oncogene. 2013 Jun 6;32(23):2848-57. doi: 10.1038/onc.2012.306. Epub 2012 Jul 16.
• [159] Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.Mol Cancer. 2014 May 29;13:130. doi: 10.1186/1476-4598-13-130.
• [160] Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma.Cancer Lett. 2018 Jul 1;425:65-77. doi: 10.1016/j.canlet.2018.03.031. Epub 2018 Mar 23.
• [161] Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling.Cancer Sci. 2010 Jan;101(1):259-66. doi: 10.1111/j.1349-7006.2009.01359.x. Epub 2009 Sep 10.
• [162] Usefulness of immunohistochemical staining for MUC5AC in differentiating primary pancreatic cancer from pancreatic metastasis of breast cancer.Diagn Cytopathol. 2019 Oct;47(10):1037-1041. doi: 10.1002/dc.24249. Epub 2019 Jun 6.
• [163] The E3 ubiquitin ligase NEDD4 is translationally upregulated and facilitates pancreatic cancer.Oncotarget. 2017 Mar 21;8(12):20288-20296. doi: 10.18632/oncotarget.15446.
• [164] Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.Neoplasia. 2017 Jun;19(6):509-518. doi: 10.1016/j.neo.2017.04.003. Epub 2017 May 20.
• [165] Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma.Oncotarget. 2016 Oct 25;7(43):69489-69506. doi: 10.18632/oncotarget.11060.
• [166] Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2R(null) (NOG) mice.Am J Pathol. 2014 Mar;184(3):674-85. doi: 10.1016/j.ajpath.2013.11.014. Epub 2014 Jan 9.
• [167] MiR-429 suppresses neurotrophin-3 to alleviate perineural invasion of pancreatic cancer.Biochem Biophys Res Commun. 2018 Nov 10;505(4):1077-1083. doi: 10.1016/j.bbrc.2018.09.147. Epub 2018 Oct 9.
• [168] Preclinical Evaluation of (68)Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis.Mol Pharm. 2019 Jun 3;16(6):2776-2784. doi: 10.1021/acs.molpharmaceut.9b00283. Epub 2019 May 3.
• [169] Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.Mol Cancer Res. 2017 Apr;15(4):478-488. doi: 10.1158/1541-7786.MCR-16-0337. Epub 2017 Jan 4.
• [170] UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.PLoS One. 2017 Aug 1;12(8):e0182044. doi: 10.1371/journal.pone.0182044. eCollection 2017.
• [171] Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein.Oncogene. 2018 Mar;37(13):1730-1742. doi: 10.1038/s41388-017-0086-y. Epub 2018 Jan 16.
• [172] Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.Cancer Res. 2019 Sep 1;79(17):4491-4502. doi: 10.1158/0008-5472.CAN-18-3645. Epub 2019 Jul 4.
• [173] Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC.Carcinogenesis. 2018 Dec 31;39(12):1548-1559. doi: 10.1093/carcin/bgy114.
• [174] Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer.Cancer Lett. 2018 Sep 28;432:237-250. doi: 10.1016/j.canlet.2018.04.035. Epub 2018 Apr 28.
• [175] Pancreatic adenocarcinomas with mature blood vessels have better overall survival.Sci Rep. 2019 Feb 4;9(1):1310. doi: 10.1038/s41598-018-37909-5.
• [176] PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.Cancer Res. 2019 Jan 1;79(1):133-145. doi: 10.1158/0008-5472.CAN-18-1968. Epub 2018 Oct 24.
• [177] Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations.Nat Commun. 2018 Sep 11;9(1):3688. doi: 10.1038/s41467-018-06136-x.
• [178] Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.Eur J Surg Oncol. 2019 Feb;45(2):218-224. doi: 10.1016/j.ejso.2018.10.050. Epub 2018 Oct 11.
• [179] Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas andBile Duct.Gastroenterology. 2020 Feb;158(3):573-582.e2. doi: 10.1053/j.gastro.2019.10.028. Epub 2019 Oct 31.
• [180] PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.Cell Oncol (Dordr). 2020 Feb;43(1):51-62. doi: 10.1007/s13402-019-00435-1. Epub 2019 Sep 13.
• [181] Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.Pancreatology. 2017 Jan-Feb;17(1):89-94. doi: 10.1016/j.pan.2016.12.004. Epub 2016 Dec 15.
• [182] Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis.Onco Targets Ther. 2019 Feb 1;12:1007-1020. doi: 10.2147/OTT.S176101. eCollection 2019.
• [183] Evaluation of insulin-like growth factor (IGF-1) and retinol binding protein (RBP-4) levels in patients with newly diagnosed pancreatic adenocarcinoma (PDAC).Pancreatology. 2017 Jul-Aug;17(4):623-628. doi: 10.1016/j.pan.2017.04.001. Epub 2017 Apr 4.
• [184] Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.Cancer Immunol Immunother. 2018 Feb;67(2):195-207. doi: 10.1007/s00262-017-2077-9. Epub 2017 Oct 17.
• [185] Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.Nat Med. 2017 Jan;23(1):60-68. doi: 10.1038/nm.4219. Epub 2016 Nov 21.
• [186] Axon guidance factor SLIT2 inhibits neural invasion and metastasis in pancreatic cancer.Cancer Res. 2014 Mar 1;74(5):1529-40. doi: 10.1158/0008-5472.CAN-13-1012. Epub 2014 Jan 21.
• [187] ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1.Cancers (Basel). 2019 Nov 27;11(12):1881. doi: 10.3390/cancers11121881.
• [188] The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).Clin Cancer Res. 2015 Dec 15;21(24):5563-77. doi: 10.1158/1078-0432.CCR-15-0485. Epub 2015 Jul 30.
• [189] Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors.Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1147-E1156. doi: 10.1073/pnas.1717802115. Epub 2018 Jan 19.
• [190] Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype.Mol Cancer. 2012 Apr 3;11:19. doi: 10.1186/1476-4598-11-19.
• [191] Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.Cancer Sci. 2011 Nov;102(11):2029-37. doi: 10.1111/j.1349-7006.2011.02053.x. Epub 2011 Sep 13.
• [192] SERPINB5 Promoter Hypomethylation Differentiates Pancreatic Ductal Adenocarcinoma From Pancreatitis.Pancreas. 2016 May-Jun;45(5):743-7. doi: 10.1097/MPA.0000000000000526.
• [193] SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma.Am J Cancer Res. 2019 Feb 1;9(2):363-377. eCollection 2019.
• [194] Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?.Cancers (Basel). 2019 Oct 23;11(11):1621. doi: 10.3390/cancers11111621.
• [195] Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma.Biomed Res Int. 2015;2015:593572. doi: 10.1155/2015/593572. Epub 2015 May 27.
• [196] A potential prognostic marker and therapeutic target: SPOCK1 promotes the proliferation, metastasis, and apoptosis of pancreatic ductal adenocarcinoma cells.J Cell Biochem. 2020 Jan;121(1):743-754. doi: 10.1002/jcb.29320. Epub 2019 Sep 3.
• [197] Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer.Mol Biol Cell. 2016 Nov 7;27(22):3659-3672. doi: 10.1091/mbc.E16-06-0427. Epub 2016 Sep 28.
• [198] Elevated expression of Tiam1 is associated with poor prognosis and promotes tumor progression in pancreatic cancer.Onco Targets Ther. 2018 Jul 26;11:4367-4375. doi: 10.2147/OTT.S171425. eCollection 2018.
• [199] Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma.Pancreas. 2019 Jan;48(1):43-48. doi: 10.1097/MPA.0000000000001195.
• [200] Downregulation of TRAIL-Receptor 1 Increases TGF Type II Receptor Expression and TGF Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells.Cancers (Basel). 2018 Oct 25;10(11):399. doi: 10.3390/cancers10110399.
• [201] The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection.Cancers (Basel). 2019 May 29;11(6):745. doi: 10.3390/cancers11060745.
• [202] Ion channels in control of pancreatic stellate cell migration.Oncotarget. 2017 Jan 3;8(1):769-784. doi: 10.18632/oncotarget.13647.
• [203] Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.Gastroenterology. 2019 May;156(6):1742-1752. doi: 10.1053/j.gastro.2019.01.039. Epub 2019 Jan 22.
• [204] USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1.Am J Cancer Res. 2019 Aug 1;9(8):1722-1733. eCollection 2019.
• [205] Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5-WT1-E-cadherin signalling pathway in pancreatic ductal adenocarcinoma.J Cell Mol Med. 2020 Jan;24(2):1370-1382. doi: 10.1111/jcmm.14813. Epub 2019 Dec 17.
• [206] Placental mesenchymal dysplasia with a good outcome: A case report.J Obstet Gynaecol Res. 2019 Nov;45(11):2284-2288. doi: 10.1111/jog.14095. Epub 2019 Aug 26.
• [207] B7-H4 expression in normal and diseased human islet cells.Pancreas. 2014 Jan;43(1):128-34. doi: 10.1097/MPA.0b013e31829695d2.
• [208] InVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.Cell Rep. 2016 Jun 28;16(1):133-147. doi: 10.1016/j.celrep.2016.05.063. Epub 2016 Jun 16.
• [209] Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma.Mol Ther Nucleic Acids. 2020 Mar 6;19:228-239. doi: 10.1016/j.omtn.2019.11.010. Epub 2019 Nov 20.
• [210] Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.J Transl Med. 2017 Jun 2;15(1):126. doi: 10.1186/s12967-017-1227-3.
• [211] Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.Clin Cancer Res. 2020 Mar 15;26(6):1338-1348. doi: 10.1158/1078-0432.CCR-19-1728. Epub 2019 Dec 12.
• [212] The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.EBioMedicine. 2019 Jun;44:419-430. doi: 10.1016/j.ebiom.2019.05.035. Epub 2019 May 22.
• [213] YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.JCI Insight. 2019 Nov 1;4(21):e130811. doi: 10.1172/jci.insight.130811.
• [214] Stromal mesenchymal stem cells facilitate pancreatic cancer progression by regulating specific secretory molecules through mutual cellular interaction.J Cancer. 2018 Jul 30;9(16):2916-2929. doi: 10.7150/jca.24415. eCollection 2018.
• [215] Anti-tumor activity of antibody drug conjugate targeting aspartate--hydroxylase in pancreatic ductal adenocarcinoma.Cancer Lett. 2019 May 1;449:87-98. doi: 10.1016/j.canlet.2019.02.006. Epub 2019 Feb 12.
• [216] Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.Mol Cell. 2017 Aug 17;67(4):685-701.e6. doi: 10.1016/j.molcel.2017.07.014. Epub 2017 Aug 10.
• [217] Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolism.Exp Mol Med. 2019 Nov 29;51(11):1-11. doi: 10.1038/s12276-019-0350-z.
• [218] High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma.Gene. 2019 Jun 15;701:15-22. doi: 10.1016/j.gene.2019.02.081. Epub 2019 Mar 18.
• [219] High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients.Eur J Surg Oncol. 2019 Feb;45(2):207-212. doi: 10.1016/j.ejso.2018.09.020. Epub 2018 Oct 21.
• [220] Oncogenic Activities Of UBE2S Mediated By VHL/HIF-1/STAT3 Signal Via The Ubiquitin-Proteasome System In PDAC.Onco Targets Ther. 2019 Nov 15;12:9767-9781. doi: 10.2147/OTT.S228522. eCollection 2019.
• [221] miR-124 Suppresses Pancreatic Ductal Adenocarcinoma Growth by Regulating Monocarboxylate Transporter 1-Mediated Cancer Lactate Metabolism.Cell Physiol Biochem. 2018;50(3):924-935. doi: 10.1159/000494477. Epub 2018 Oct 24.
• [222] Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.Pancreas. 2017 May/Jun;46(5):684-689. doi: 10.1097/MPA.0000000000000807.
• [223] Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21.
• [224] DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma.J Immunol Res. 2019 Sep 8;2019:8656282. doi: 10.1155/2019/8656282. eCollection 2019.
• [225] Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma.Exp Ther Med. 2018 Jul;16(1):53-60. doi: 10.3892/etm.2018.6172. Epub 2018 May 16.
• [226] KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.Cancer Res. 2018 Mar 15;78(6):1444-1456. doi: 10.1158/0008-5472.CAN-17-2873. Epub 2018 Jan 10.
• [227] Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice.Oncotarget. 2015 Dec 1;6(38):41063-76. doi: 10.18632/oncotarget.5729.
• [228] Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1.Gastroenterology. 2018 Sep;155(3):892-908.e6. doi: 10.1053/j.gastro.2018.05.041. Epub 2018 Jun 2.
• [229] Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin.Cancer Res. 2014 May 1;74(9):2455-64. doi: 10.1158/0008-5472.CAN-13-3009. Epub 2014 Mar 5.
• [230] Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues.Int J Biol Macromol. 2018 Jun;112:33-45. doi: 10.1016/j.ijbiomac.2018.01.148. Epub 2018 Feb 2.
• [231] Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer.Oncotarget. 2016 Jun 1;8(34):56081-56094. doi: 10.18632/oncotarget.9760. eCollection 2017 Aug 22.
• [232] Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28.
• [233] Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.Br J Cancer. 2014 Oct 28;111(9):1780-7. doi: 10.1038/bjc.2014.460. Epub 2014 Aug 19.
• [234] Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.Virology. 2015 Nov;485:340-54. doi: 10.1016/j.virol.2015.08.003. Epub 2015 Aug 29.
• [235] Tumor-Stroma IL1-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.Cancer Res. 2018 Apr 1;78(7):1700-1712. doi: 10.1158/0008-5472.CAN-17-1366. Epub 2018 Jan 23.
• [236] Integrin 1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110 signaling.Biochem Biophys Res Commun. 2018 Oct 20;505(1):215-221. doi: 10.1016/j.bbrc.2018.09.061. Epub 2018 Sep 20.
• [237] Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.Oncotarget. 2016 Mar 29;7(13):17087-102. doi: 10.18632/oncotarget.7718.
• [238] Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome.Pancreatology. 2018 Dec;18(8):945-953. doi: 10.1016/j.pan.2018.09.006. Epub 2018 Sep 25.
• [239] Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2019 May;145(5):1165-1178. doi: 10.1007/s00432-019-02863-w. Epub 2019 Feb 18.
• [240] Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer.Oncotarget. 2017 Aug 2;8(39):66098-66111. doi: 10.18632/oncotarget.19802. eCollection 2017 Sep 12.
• [241] Regulation of pancreatic stellate cell activation by Notch3.BMC Cancer. 2018 Jan 5;18(1):36. doi: 10.1186/s12885-017-3957-2.
• [242] iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer.Mol Cancer Ther. 2018 Nov;17(11):2377-2388. doi: 10.1158/1535-7163.MCT-17-1090. Epub 2018 Aug 10.
• [243] Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?.Oncotarget. 2017 Feb 21;8(8):14173-14191. doi: 10.18632/oncotarget.13309.
• [244] Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.J Exp Clin Cancer Res. 2019 May 14;38(1):191. doi: 10.1186/s13046-019-1191-2.
• [245] MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.Oncotarget. 2015 Jun 10;6(16):14440-55. doi: 10.18632/oncotarget.3885.
• [246] Overexpression of C16orf74 is involved in aggressive pancreatic cancers.Oncotarget. 2016 Jul 28;8(31):50460-50475. doi: 10.18632/oncotarget.10912. eCollection 2017 Aug 1.
• [247] Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.Int J Cancer. 2018 Jan 15;142(2):290-296. doi: 10.1002/ijc.31047. Epub 2017 Oct 16.
• [248] The pancreatic cancer secreted REG4 promotes macrophage polarization to M2 through EGFR/AKT/CREB pathway.Oncol Rep. 2016 Jan;35(1):189-96. doi: 10.3892/or.2015.4357. Epub 2015 Oct 29.
• [249] Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.Pancreas. 2016 Aug;45(7):1036-47. doi: 10.1097/MPA.0000000000000571.
• [250] B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.Cancer Sci. 2019 Feb;110(2):530-539. doi: 10.1111/cas.13914. Epub 2019 Jan 16.
• [251] Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.Cancer Res. 2017 May 15;77(10):2647-2660. doi: 10.1158/0008-5472.CAN-16-1986. Epub 2017 Mar 1.
• [252] pH-sensitive K(+) channel TREK-1 is a novel target in pancreatic cancer.Biochim Biophys Acta. 2016 Oct;1862(10):1994-2003. doi: 10.1016/j.bbadis.2016.07.009. Epub 2016 Jul 19.
• [253] The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.Oncotarget. 2015 May 10;6(13):10853-67. doi: 10.18632/oncotarget.3414.
• [254] TGF--induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.Carcinogenesis. 2016 Nov 1;37(11):1041-1051. doi: 10.1093/carcin/bgw093.
• [255] Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis.Cancer Sci. 2009 Mar;100(3):457-64. doi: 10.1111/j.1349-7006.2008.01058.x. Epub 2008 Dec 16.
• [256] Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas.Oncogene. 2019 Feb;38(8):1211-1224. doi: 10.1038/s41388-018-0510-y. Epub 2018 Sep 24.
• [257] Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).Carcinogenesis. 2013 Sep;34(9):2090-8. doi: 10.1093/carcin/bgt170. Epub 2013 May 20.
• [258] Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.PLoS One. 2016 Mar 29;11(3):e0152300. doi: 10.1371/journal.pone.0152300. eCollection 2016.
• [259] Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.J Natl Cancer Inst. 2014 Jan;106(1):djt346. doi: 10.1093/jnci/djt346. Epub 2013 Dec 3.
• [260] Cannabinoids in pancreatic cancer: correlation with survival and pain.Int J Cancer. 2008 Feb 15;122(4):742-50. doi: 10.1002/ijc.23114.
• [261] Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.Oncol Res. 2018 Aug 23;26(7):1123-1131. doi: 10.3727/096504018X15166223632406. Epub 2018 Jan 31.
• [262] Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions.Nat Commun. 2017 Jul 7;8:16031. doi: 10.1038/ncomms16031.
• [263] A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.Mol Oncol. 2018 Sep;12(9):1526-1539. doi: 10.1002/1878-0261.12364. Epub 2018 Aug 29.
• [264] Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition.J Cancer. 2019 Jun 10;10(16):3860-3870. doi: 10.7150/jca.31291. eCollection 2019.
• [265] ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.Mol Cancer. 2016 May 4;15(1):32. doi: 10.1186/s12943-016-0516-4.
• [266] Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma.PLoS One. 2017 Feb 10;12(2):e0171985. doi: 10.1371/journal.pone.0171985. eCollection 2017.
• [267] BAG3 Suppresses Loading of Ago2 to IL6 mRNA in Pancreatic Ductal Adenocarcinoma.Front Oncol. 2019 Apr 2;9:225. doi: 10.3389/fonc.2019.00225. eCollection 2019.
• [268] Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells.Cancer Biol Ther. 2007 Mar;6(3):367-76. doi: 10.4161/cbt.6.3.3704. Epub 2007 Mar 13.
• [269] Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.J Clin Pathol. 2017 Jul;70(7):619-624. doi: 10.1136/jclinpath-2016-204028. Epub 2016 Dec 15.
• [270] Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma.Oncogene. 2015 Aug 6;34(32):4238-47. doi: 10.1038/onc.2014.357. Epub 2014 Nov 10.
• [271] The C/EBP-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1.Cancer Lett. 2018 May 1;421:63-72. doi: 10.1016/j.canlet.2018.02.020. Epub 2018 Feb 16.
• [272] Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 9;8(34):56428-56442. doi: 10.18632/oncotarget.17701. eCollection 2017 Aug 22.
• [273] COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.Mol Carcinog. 2017 Feb;56(2):607-624. doi: 10.1002/mc.22520. Epub 2016 Jul 8.
• [274] CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.Cancer Biol Ther. 2019;20(9):1290-1299. doi: 10.1080/15384047.2019.1632143. Epub 2019 Jul 16.
• [275] Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.Diagn Pathol. 2017 May 30;12(1):42. doi: 10.1186/s13000-017-0633-4.
• [276] Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for earlystage pancreatic ductal adenocarcinoma.Oncol Rep. 2019 Jul;42(1):79-90. doi: 10.3892/or.2019.7135. Epub 2019 Apr 24.
• [277] Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma.Cancer Sci. 2017 Nov;108(11):2122-2129. doi: 10.1111/cas.13396. Epub 2017 Oct 8.
• [278] FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis.Oncogene. 2018 Feb 8;37(6):697-709. doi: 10.1038/onc.2017.358. Epub 2017 Oct 23.
• [279] Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.World J Gastroenterol. 2017 Aug 21;23(31):5764-5772. doi: 10.3748/wjg.v23.i31.5764.
• [280] Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.J Mol Cell Biol. 2017 Dec 1;9(6):504-515. doi: 10.1093/jmcb/mjx043.
• [281] MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 Jul 24;9(8):807. doi: 10.1038/s41419-018-0839-8.
• [282] EFNB2 acts as the target of miR-557 to facilitate cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma by bioinformatics analysis and verification.Am J Transl Res. 2018 Nov 15;10(11):3514-3528. eCollection 2018.
• [283] EI24 Suppresses Tumorigenesis in Pancreatic Cancer via Regulating c-Myc.Gastroenterol Res Pract. 2018 Oct 2;2018:2626545. doi: 10.1155/2018/2626545. eCollection 2018.
• [284] Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma.Onco Targets Ther. 2019 Apr 15;12:2853-2859. doi: 10.2147/OTT.S202101. eCollection 2019.
• [285] ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells.Am J Transl Res. 2019 Jul 15;11(7):4470-4480. eCollection 2019.
• [286] EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through -catenin/ID2 pathway.Cancer Lett. 2016 Oct 1;380(2):403-412. doi: 10.1016/j.canlet.2016.06.021. Epub 2016 Jul 1.
• [287] FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 Jan 18;9(2):34. doi: 10.1038/s41419-017-0052-1.
• [288] Membranous CD24 drives the epithelial phenotype of pancreatic cancer.Oncotarget. 2016 Aug 2;7(31):49156-49168. doi: 10.18632/oncotarget.9402.
• [289] Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.Gastroenterology. 2016 Dec;151(6):1218-1231. doi: 10.1053/j.gastro.2016.08.040. Epub 2016 Aug 28.
• [290] GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma.Mol Med Rep. 2018 Mar;17(3):4187-4194. doi: 10.3892/mmr.2018.8430. Epub 2018 Jan 15.
• [291] High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5.Biochem Biophys Res Commun. 2018 Feb 26;497(1):73-79. doi: 10.1016/j.bbrc.2018.02.023. Epub 2018 Feb 3.
• [292] Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.Mol Cancer. 2019 May 20;18(1):96. doi: 10.1186/s12943-019-1023-1.
• [293] HMGN5 promotes proliferation and invasion via the activation of Wnt/-catenin signaling pathway in pancreatic ductal adenocarcinoma.Oncol Lett. 2018 Sep;16(3):4013-4019. doi: 10.3892/ol.2018.9090. Epub 2018 Jul 5.
• [294] miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7.Diagn Pathol. 2014 Sep 3;9:171. doi: 10.1186/s13000-014-0171-2.
• [295] Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.Cell Death Dis. 2018 Feb 7;9(2):161. doi: 10.1038/s41419-017-0196-z.
• [296] Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2017 Jun;143(6):1061-1068. doi: 10.1007/s00432-017-2351-4. Epub 2017 Feb 17.
• [297] IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC.Cell Rep. 2016 May 31;15(9):1876-83. doi: 10.1016/j.celrep.2016.04.083. Epub 2016 May 19.
• [298] The Insulin-Like Growth Factor 2 mRNA Binding Protein IMP2/IGF2BP2 is Overexpressed and Correlates with Poor Survival in Pancreatic Cancer.Int J Mol Sci. 2019 Jun 29;20(13):3204. doi: 10.3390/ijms20133204.
• [299] IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis.Pancreas. 2019 Jan;48(1):94-98. doi: 10.1097/MPA.0000000000001198.
• [300] KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model.Oncogene. 2017 Sep 28;36(39):5532-5543. doi: 10.1038/onc.2017.155. Epub 2017 Jun 5.
• [301] Krppel-like factor 9 suppressed tumorigenicity of the pancreatic ductal adenocarcinoma by negatively regulating frizzled-5.Biochem Biophys Res Commun. 2018 May 23;499(4):815-821. doi: 10.1016/j.bbrc.2018.03.229. Epub 2018 Apr 4.
• [302] Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.Cancer Chemother Pharmacol. 2018 Jan;81(1):141-153. doi: 10.1007/s00280-017-3477-4. Epub 2017 Nov 17.
• [303] LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.J Exp Clin Cancer Res. 2019 Feb 13;38(1):75. doi: 10.1186/s13046-019-1088-0.
• [304] Latent Transforming Growth Factor Binding Protein 2 (LTBP2) as a Novel Biomarker for the Diagnosis and Prognosis of Pancreatic Carcinoma.Med Sci Monit. 2017 Jul 3;23:3232-3239. doi: 10.12659/msm.905284.
• [305] Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma.Cell Death Differ. 2019 Jan;26(2):382-393. doi: 10.1038/s41418-018-0207-3. Epub 2018 Oct 3.
• [306] Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy.Cancer Manag Res. 2018 Sep 5;10:3255-3271. doi: 10.2147/CMAR.S171293. eCollection 2018.
• [307] SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.Oncogene. 2018 Feb 15;37(7):912-923. doi: 10.1038/onc.2017.393. Epub 2017 Oct 23.
• [308] Targeting Pancreatic Stellate Cells in Cancer.Trends Cancer. 2019 Feb;5(2):128-142. doi: 10.1016/j.trecan.2019.01.001. Epub 2019 Feb 1.
• [309] Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.HPB (Oxford). 2018 Jun;20(6):563-572. doi: 10.1016/j.hpb.2017.12.003. Epub 2018 Jan 17.
• [310] High expression of diffuse panbronchiolitis critical region 1 gene promotes cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Jan 8;495(2):1908-1914. doi: 10.1016/j.bbrc.2017.12.031. Epub 2017 Dec 11.
• [311] Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2017 Aug;213(8):964-968. doi: 10.1016/j.prp.2017.04.024. Epub 2017 May 4.
• [312] Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma.Surg Today. 2018 May;48(5):510-516. doi: 10.1007/s00595-017-1618-3. Epub 2017 Dec 18.
• [313] Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.Cell Death Dis. 2018 Feb 12;9(2):210. doi: 10.1038/s41419-017-0191-4.
• [314] Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.DNA Repair (Amst). 2019 Nov;83:102644. doi: 10.1016/j.dnarep.2019.102644. Epub 2019 Jul 5.
• [315] Amphipathic helical peptides hamper protein-protein interactions of the intrinsically disordered chromatin nuclear protein 1 (NUPR1).Biochim Biophys Acta Gen Subj. 2018 Jun;1862(6):1283-1295. doi: 10.1016/j.bbagen.2018.03.009. Epub 2018 Mar 10.
• [316] OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM.Pancreatology. 2019 Jul;19(5):751-759. doi: 10.1016/j.pan.2019.01.009. Epub 2019 Jan 31.
• [317] PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.Biochem Biophys Res Commun. 2018 Jun 27;501(3):654-660. doi: 10.1016/j.bbrc.2018.05.039. Epub 2018 May 16.
• [318] 2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.Cancer Lett. 2016 Apr 1;373(1):67-76. doi: 10.1016/j.canlet.2016.01.026. Epub 2016 Jan 21.
• [319] High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.BMC Cancer. 2019 May 14;19(1):452. doi: 10.1186/s12885-019-5616-2.
• [320] eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.Cancer Res. 2017 Apr 15;77(8):1997-2007. doi: 10.1158/0008-5472.CAN-16-2594. Epub 2017 Apr 5.
• [321] Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer.Cancer Res. 2016 Nov 15;76(22):6507-6519. doi: 10.1158/0008-5472.CAN-15-2864. Epub 2016 Sep 9.
• [322] An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.Proc Natl Acad Sci U S A. 2019 Nov 12;116(46):23264-23273. doi: 10.1073/pnas.1914557116. Epub 2019 Oct 29.
• [323] PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells.Oncotarget. 2016 Feb 16;7(7):7801-15. doi: 10.18632/oncotarget.6848.
• [324] Expression of polymeric immunoglobulin receptor and stromal activity in pancreatic ductal adenocarcinoma.Pancreatology. 2017 Mar-Apr;17(2):295-302. doi: 10.1016/j.pan.2017.01.013. Epub 2017 Feb 1.
• [325] Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 May 1;9(5):453. doi: 10.1038/s41419-018-0486-0.
• [326] Oxidative stress and mitochondrial dynamics malfunction are linked in Pelizaeus-Merzbacher disease.Brain Pathol. 2018 Sep;28(5):611-630. doi: 10.1111/bpa.12571. Epub 2017 Dec 26.
• [327] Nano-biotinylated liposome-based immunoassay for the ultrasensitive detection of protein biomarker in urine.Talanta. 2018 Mar 1;179:472-477. doi: 10.1016/j.talanta.2017.11.031. Epub 2017 Nov 21.
• [328] Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.Cell Death Dis. 2017 Sep 7;8(9):e3033. doi: 10.1038/cddis.2017.424.
• [329] Ro60/SSA levels are increased and promote the progression of pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Jan 22;495(4):2519-2524. doi: 10.1016/j.bbrc.2017.12.124. Epub 2017 Dec 22.
• [330] Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts.Oncol Res. 2019 Aug 8;27(8):945-956. doi: 10.3727/096504019X15555408784978. Epub 2019 Apr 17.
• [331] Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 18;8(38):62953-62961. doi: 10.18632/oncotarget.17972. eCollection 2017 Sep 8.
• [332] Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.Nanoscale. 2017 Jul 27;9(29):10327-10334. doi: 10.1039/c7nr03042h.
• [333] Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway.Cancer Lett. 2017 Jul 1;397:12-22. doi: 10.1016/j.canlet.2017.03.014. Epub 2017 Mar 14.
• [334] SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-B axis.Int J Oncol. 2017 Oct;51(4):1104-1114. doi: 10.3892/ijo.2017.4111. Epub 2017 Aug 31.
• [335] Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays.Oncogene. 2008 Mar 20;27(13):1951-60. doi: 10.1038/sj.onc.1210832. Epub 2007 Oct 22.
• [336] Increased SOX9 Expression in Premalignant and Malignant Pancreatic Neoplasms.Ann Surg Oncol. 2019 Feb;26(2):628-634. doi: 10.1245/s10434-018-6925-4. Epub 2018 Oct 24.
• [337] Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10.J Cancer. 2018 Feb 1;9(4):711-725. doi: 10.7150/jca.21803. eCollection 2018.
• [338] MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2018 Apr 3;37(1):76. doi: 10.1186/s13046-018-0739-x.
• [339] Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF- signaling pathway.J Exp Clin Cancer Res. 2019 Jul 15;38(1):310. doi: 10.1186/s13046-019-1313-x.
• [340] Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2019 Nov 12;38(1):466. doi: 10.1186/s13046-019-1436-0.
• [341] Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects.Sci Rep. 2019 Oct 29;9(1):15471. doi: 10.1038/s41598-019-51881-8.
• [342] lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP.Clin Cancer Res. 2020 Apr 1;26(7):1736-1748. doi: 10.1158/1078-0432.CCR-19-0674. Epub 2019 Dec 12.
• [343] ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.Mol Med Rep. 2013 Mar;7(3):991-7. doi: 10.3892/mmr.2013.1272. Epub 2013 Jan 11.
• [344] Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma.Dig Dis Sci. 2011 Apr;56(4):1090-8. doi: 10.1007/s10620-010-1416-x. Epub 2010 Oct 7.
• [345] Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.Dev Cell. 2012 Jan 17;22(1):131-45. doi: 10.1016/j.devcel.2011.11.008. Epub 2011 Dec 22.
• [346] Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases.Oncogene. 2014 Sep 4;33(36):4485-95. doi: 10.1038/onc.2013.392. Epub 2013 Sep 30.
• [347] FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25.
• [348] The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2015 Dec;36(12):9961-8. doi: 10.1007/s13277-015-3752-0. Epub 2015 Jul 16.
• [349] Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma.BMC Cancer. 2014 Aug 7;14:571. doi: 10.1186/1471-2407-14-571.
• [350] Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.Br J Cancer. 2011 Jul 12;105(2):288-95. doi: 10.1038/bjc.2011.217. Epub 2011 Jun 28.
• [351] NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.Mol Cell Biochem. 2015 Dec;410(1-2):25-35. doi: 10.1007/s11010-015-2535-7. Epub 2015 Aug 15.
• [352] Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.Cancer Lett. 2009 May 8;277(1):72-81. doi: 10.1016/j.canlet.2008.11.028. Epub 2008 Dec 31.
• [353] High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).Tumour Biol. 2015 Dec;36(12):9189-99. doi: 10.1007/s13277-015-3625-6. Epub 2015 Jun 19.
• [354] Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.Cancer Med. 2020 Feb;9(3):859-871. doi: 10.1002/cam4.2699. Epub 2019 Dec 6.
• [355] Clinicopathological and prognostic significance of myofibrillogenesis regulator-1 protein expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2013 Oct;34(5):2983-7. doi: 10.1007/s13277-013-0862-4. Epub 2013 May 22.
• [356] Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.PLoS One. 2015 Jun 8;10(6):e0129012. doi: 10.1371/journal.pone.0129012. eCollection 2015.
• [357] Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.Mol Cancer Ther. 2014 Jan;13(1):122-33. doi: 10.1158/1535-7163.MCT-12-1232. Epub 2013 Nov 12.
• [358] Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.World J Gastroenterol. 2015 Jun 7;21(21):6621-30. doi: 10.3748/wjg.v21.i21.6621.
• [359] Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.BMC Cancer. 2014 Aug 8;14:578. doi: 10.1186/1471-2407-14-578.
• [360] Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells.Cancer Res. 2014 Aug 15;74(16):4353-63. doi: 10.1158/0008-5472.CAN-14-0181. Epub 2014 Jun 5.
• [361] Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.Int J Mol Sci. 2011;12(8):4953-63. doi: 10.3390/ijms12084953. Epub 2011 Aug 3.
• [362] TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.PLoS One. 2015 Dec 28;10(12):e0144969. doi: 10.1371/journal.pone.0144969. eCollection 2015.
• [363] TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):94-8. doi: 10.1016/s1499-3872(13)60012-0.
• [364] Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells.Cancer Res. 2010 May 15;70(10):4024-33. doi: 10.1158/0008-5472.CAN-09-4444. Epub 2010 May 4.
• [365] A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling.Sci Adv. 2019 Aug 28;5(8):eaav6789. doi: 10.1126/sciadv.aav6789. eCollection 2019 Aug.
• [366] Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study.Int J Cancer. 2019 Mar 15;144(6):1275-1283. doi: 10.1002/ijc.31928. Epub 2018 Nov 12.
• [367] ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.
• [368] Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.Cancer Chemother Pharmacol. 2011 Sep;68(3):571-82. doi: 10.1007/s00280-010-1514-7. Epub 2010 Nov 26.
• [369] The Anthrax Toxin Receptor 1 (ANTXR1) Is Enriched in Pancreatic Cancer Stem Cells Derived from Primary Tumor Cultures.Stem Cells Int. 2019 May 2;2019:1378639. doi: 10.1155/2019/1378639. eCollection 2019.
• [370] Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation.Cancer Sci. 2018 Jun;109(6):2013-2026. doi: 10.1111/cas.13610. Epub 2018 May 22.
• [371] Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer.J Pathol. 2020 Feb;250(2):123-125. doi: 10.1002/path.5355. Epub 2019 Dec 2.
• [372] SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.Biochem Biophys Res Commun. 2019 Mar 19;510(4):508-514. doi: 10.1016/j.bbrc.2019.01.109. Epub 2019 Feb 5.
• [373] Role of BCL9L in transforming growth factor- (TGF-)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.Oncotarget. 2016 Nov 8;7(45):73725-73738. doi: 10.18632/oncotarget.12455.
• [374] Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment.Mol Oncol. 2018 Jun;12(7):1104-1124. doi: 10.1002/1878-0261.12314. Epub 2018 May 21.
• [375] GLI1 interferes with the DNA mismatch repair system in pancreatic cancer through BHLHE41-mediated suppression of MLH1.Cancer Res. 2013 Dec 15;73(24):7313-23. doi: 10.1158/0008-5472.CAN-13-2008. Epub 2013 Oct 28.
• [376] Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.Cancer Discov. 2019 Sep;9(9):1268-1287. doi: 10.1158/2159-8290.CD-18-1409. Epub 2019 Jul 1.
• [377] Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes.PLoS One. 2013 Sep 17;8(9):e73968. doi: 10.1371/journal.pone.0073968. eCollection 2013.
• [378] BTN3A is a prognosis marker and a promising target for V9V2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).Oncoimmunology. 2017 Sep 21;7(1):e1372080. doi: 10.1080/2162402X.2017.1372080. eCollection 2017.
• [379] Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target.Mol Cancer Ther. 2020 Jan;19(1):187-198. doi: 10.1158/1535-7163.MCT-19-0491. Epub 2019 Oct 9.
• [380] A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.J Pharmacol Exp Ther. 2019 Sep;370(3):894-901. doi: 10.1124/jpet.118.255372. Epub 2019 Jan 25.
• [381] COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.Mol Cancer. 2015 May 29;14:109. doi: 10.1186/s12943-015-0386-1.
• [382] Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.Proteomics. 2014 Apr;14(7-8):945-55. doi: 10.1002/pmic.201300402. Epub 2014 Mar 3.
• [383] Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.Cancer Res. 2013 Apr 1;73(7):2357-67. doi: 10.1158/0008-5472.CAN-12-3359. Epub 2013 Jan 31.
• [384] Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.Cancer Immunol Immunother. 2012 Nov;61(11):2113-23. doi: 10.1007/s00262-012-1279-4. Epub 2012 May 11.
• [385] MiR-345-5p functions as a tumor suppressor in pancreatic cancer by directly targeting CCL8.Biomed Pharmacother. 2019 Mar;111:891-900. doi: 10.1016/j.biopha.2018.12.121. Epub 2019 Jan 7.
• [386] Prognostic Values of CD38(+)CD101(+)PD1(+)CD8(+) T Cells in Pancreatic Cancer.Immunol Invest. 2019 Jul;48(5):466-479. doi: 10.1080/08820139.2019.1566356. Epub 2019 Jan 28.
• [387] Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.Biochem Biophys Res Commun. 2018 Jun 18;501(1):313-319. doi: 10.1016/j.bbrc.2018.05.024. Epub 2018 May 9.
• [388] Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood.ACS Nano. 2018 Apr 24;12(4):3311-3320. doi: 10.1021/acsnano.7b08199. Epub 2018 Mar 28.
• [389] Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas.Genes Chromosomes Cancer. 2017 May;56(5):427-435. doi: 10.1002/gcc.22447. Epub 2017 Mar 7.
• [390] Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma.Pancreas. 2017 Mar;46(3):311-322. doi: 10.1097/MPA.0000000000000743.
• [391] The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.Cancer Biol Ther. 2019;20(6):729-739. doi: 10.1080/15384047.2018.1529121. Epub 2019 Mar 27.
• [392] Targeted Delivery of C/EBP -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.Mol Ther. 2016 Jun;24(6):1106-1116. doi: 10.1038/mt.2016.60. Epub 2016 Mar 17.
• [393] Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.Cancer Sci. 2019 Sep;110(9):2846-2855. doi: 10.1111/cas.14134. Epub 2019 Aug 10.
• [394] Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma.Pancreatology. 2019 Oct;19(7):963-970. doi: 10.1016/j.pan.2019.09.005. Epub 2019 Sep 14.
• [395] KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer.Oncotarget. 2017 Mar 7;8(10):17156-17163. doi: 10.18632/oncotarget.15052.
• [396] Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer.Cancer Med. 2019 Sep;8(11):5289-5300. doi: 10.1002/cam4.2379. Epub 2019 Jul 16.
• [397] A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.PLoS One. 2018 Jun 21;13(6):e0199130. doi: 10.1371/journal.pone.0199130. eCollection 2018.
• [398] CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy.Clin Cancer Res. 2019 Mar 15;25(6):1936-1947. doi: 10.1158/1078-0432.CCR-18-2124. Epub 2019 Jan 4.
• [399] Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.Cancer Treat Rev. 2019 Nov;80:101895. doi: 10.1016/j.ctrv.2019.101895. Epub 2019 Sep 6.
• [400] CRABP-II enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression.Oncotarget. 2016 Dec 26;8(32):52432-52444. doi: 10.18632/oncotarget.14194. eCollection 2017 Aug 8.
• [401] A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination.Lab Invest. 2019 Jul;99(8):1233-1244. doi: 10.1038/s41374-018-0171-z. Epub 2019 Feb 6.
• [402] S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells.Am J Pathol. 2012 Apr;180(4):1485-94. doi: 10.1016/j.ajpath.2011.12.031. Epub 2012 Feb 11.
• [403] Loss of Disabled-2 Expression in Pancreatic Cancer Progression.Sci Rep. 2019 May 17;9(1):7532. doi: 10.1038/s41598-019-43992-z.
• [404] The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.Dis Markers. 2015;2015:379568. doi: 10.1155/2015/379568. Epub 2015 Jul 30.
• [405] Antimicrobial Peptide Human Neutrophil Peptide 1 as a Potential Link Between Chronic Inflammation and Ductal Adenocarcinoma of the Pancreas.Pancreas. 2018 May/Jun;47(5):561-567. doi: 10.1097/MPA.0000000000001054.
• [406] Comprehensive analysis of differentially expressed circRNAs revealed a ceRNA network in pancreatic ductaladenocarcinoma.Arch Med Sci. 2019 Jul;15(4):979-991. doi: 10.5114/aoms.2019.85204. Epub 2019 May 15.
• [407] Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell.Cancer Res. 2005 Jan 1;65(1):105-12.
• [408] Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic cancer.Cancer Sci. 2017 Nov;108(11):2130-2141. doi: 10.1111/cas.13347. Epub 2017 Sep 15.
• [409] miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression.Am J Transl Res. 2019 May 15;11(5):2983-2994. eCollection 2019.
• [410] Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.Oncotarget. 2016 Jan 26;7(4):4226-40. doi: 10.18632/oncotarget.6772.
• [411] Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.BMC Cancer. 2011 Jan 31;11:47. doi: 10.1186/1471-2407-11-47.
• [412] Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.J Hum Genet. 2019 Jun;64(6):521-534. doi: 10.1038/s10038-019-0584-6. Epub 2019 Mar 11.
• [413] Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma.Pathol Res Pract. 2018 Jun;214(6):840-847. doi: 10.1016/j.prp.2018.04.016. Epub 2018 May 1.
• [414] LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells.Cancer Lett. 2015 Aug 1;364(1):17-24. doi: 10.1016/j.canlet.2015.04.019. Epub 2015 Apr 23.
• [415] FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner.EMBO J. 2019 Oct 15;38(20):e102161. doi: 10.15252/embj.2019102161. Epub 2019 Sep 17.
• [416] miR-23a acts as an oncogene in pancreatic carcinoma by targeting FOXP2. J Investig Med. 2018 Mar;66(3):676-683.
• [417] FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth.Int J Cancer. 2006 Jan 1;118(1):43-54. doi: 10.1002/ijc.21257.
• [418] Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.Br J Cancer. 2016 Jun 14;114(12):1376-86. doi: 10.1038/bjc.2016.116. Epub 2016 May 17.
• [419] Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Oncotarget. 2016 Sep 20;7(38):61601-61618. doi: 10.18632/oncotarget.11202.
• [420] Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population.J Cancer Res Clin Oncol. 2019 Mar;145(3):787-796. doi: 10.1007/s00432-019-02849-8. Epub 2019 Jan 31.
• [421] Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-1/Gfi-1 axis.Cancer Lett. 2017 Jan 28;385:65-74. doi: 10.1016/j.canlet.2016.11.006. Epub 2016 Nov 11.
• [422] Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.Nature. 2013 Apr 4;496(7443):101-5. doi: 10.1038/nature12040. Epub 2013 Mar 27.
• [423] Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.Cancer Genomics Proteomics. 2015 Jan-Feb;12(1):21-30.
• [424] Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition.Cell Death Dis. 2018 Jan 19;9(2):55. doi: 10.1038/s41419-017-0089-1.
• [425] Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases.Oncotarget. 2019 Feb 1;10(10):1045-1055. doi: 10.18632/oncotarget.26620. eCollection 2019 Feb 1.
• [426] GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets.Front Pharmacol. 2018 May 22;9:431. doi: 10.3389/fphar.2018.00431. eCollection 2018.
• [427] Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.J Exp Clin Cancer Res. 2019 Feb 1;38(1):47. doi: 10.1186/s13046-019-1044-z.
• [428] Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer.Clin Cancer Res. 2003 Nov 1;9(14):5127-36.
• [429] HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.Cancer Res. 2016 Feb 1;76(3):572-81. doi: 10.1158/0008-5472.CAN-15-0671. Epub 2015 Dec 16.
• [430] Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression.Clin Cancer Res. 2019 Apr 1;25(7):2194-2205. doi: 10.1158/1078-0432.CCR-18-1955. Epub 2018 Nov 1.
• [431] Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.Clin Cancer Res. 2018 Sep 15;24(18):4444-4454. doi: 10.1158/1078-0432.CCR-17-3401. Epub 2018 Apr 16.
• [432] HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion.Oncotarget. 2017 Mar 21;8(12):20165-20178. doi: 10.18632/oncotarget.15529.
• [433] Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.Med Sci Monit. 2018 Apr 19;24:2368-2376. doi: 10.12659/msm.906313.
• [434] Acetylated HOXB9 at lysine 27 is of differential diagnostic value in patients with pancreatic ductal adenocarcinoma.Front Med. 2020 Feb;14(1):91-100. doi: 10.1007/s11684-019-0696-6. Epub 2019 Aug 2.
• [435] Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.Nat Commun. 2017 Sep 15;8(1):552. doi: 10.1038/s41467-017-00488-6.
• [436] IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.J Clin Invest. 2014 Nov;124(11):4709-22. doi: 10.1172/JCI76037. Epub 2014 Sep 24.
• [437] Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing GLUT1 mRNA.Acta Biochim Biophys Sin (Shanghai). 2019 Jul 10;51(7):743-752. doi: 10.1093/abbs/gmz048.
• [438] IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.Cancer Res. 2017 Jan 15;77(2):320-329. doi: 10.1158/0008-5472.CAN-15-1684. Epub 2017 Jan 9.
• [439] Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma.Cancer Lett. 2020 Jan 28;469:217-227. doi: 10.1016/j.canlet.2019.10.031. Epub 2019 Oct 24.
• [440] Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer.Clin Exp Metastasis. 2017 Apr;34(3-4):229-239. doi: 10.1007/s10585-017-9840-3. Epub 2017 Mar 13.
• [441] Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer.Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):113-119. doi: 10.1016/j.bbrc.2017.10.072. Epub 2017 Oct 16.
• [442] KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.J Clin Invest. 2013 Feb;123(2):727-39. doi: 10.1172/JCI64535. Epub 2013 Jan 16.
• [443] Prognostic value of Kinesin-4 family genes mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy.Cancer Med. 2019 Nov;8(15):6487-6502. doi: 10.1002/cam4.2524. Epub 2019 Sep 6.
• [444] RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer.Oncotarget. 2017 Jun 27;8(26):42537-42547. doi: 10.18632/oncotarget.16451.
• [445] Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.Clin Cancer Res. 2018 Jan 15;24(2):351-359. doi: 10.1158/1078-0432.CCR-17-2180. Epub 2017 Nov 3.
• [446] Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.Aging (Albany NY). 2019 Jun 10;11(11):3679-3703. doi: 10.18632/aging.102007.
• [447] LDHB and FABP4 are Associated With Progression and Poor Prognosis of Pancreatic Ductal Adenocarcinomas.Appl Immunohistochem Mol Morphol. 2017 May/Jun;25(5):351-357. doi: 10.1097/PAI.0000000000000306.
• [448] MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.Contrast Media Mol Imaging. 2018 Aug 26;2018:8382148. doi: 10.1155/2018/8382148. eCollection 2018.
• [449] Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma.Pancreatology. 2016 Nov-Dec;16(6):1044-1050. doi: 10.1016/j.pan.2016.09.003. Epub 2016 Sep 7.
• [450] Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele.PLoS One. 2017 Sep 21;12(9):e0184984. doi: 10.1371/journal.pone.0184984. eCollection 2017.
• [451] Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.J Exp Clin Cancer Res. 2019 Aug 5;38(1):312. doi: 10.1186/s13046-019-1308-7.
• [452] MDH1 and MPP7 Regulate Autophagy in Pancreatic Ductal Adenocarcinoma.Cancer Res. 2019 Apr 15;79(8):1884-1898. doi: 10.1158/0008-5472.CAN-18-2553. Epub 2019 Feb 14.
• [453] Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer.Nature. 2017 Feb 2;542(7639):119-123. doi: 10.1038/nature21052. Epub 2017 Jan 18.
• [454] The TALE homeodomain transcription factor MEIS1 activates the pro-metastatic melanoma cell adhesion molecule Mcam to promote migration of pancreatic cancer cells.Mol Carcinog. 2017 Mar;56(3):936-944. doi: 10.1002/mc.22547. Epub 2016 Sep 21.
• [455] Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.Pancreas. 2015 Mar;44(2):311-20. doi: 10.1097/MPA.0000000000000258.
• [456] A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.Sci Rep. 2015 Feb 6;5:8109. doi: 10.1038/srep08109.
• [457] Evaluation of MSX2 mRNA in brush cytology specimens distinguished pancreatic carcinoma from chronic pancreatitis.Cancer Sci. 2011 Jan;102(1):157-61. doi: 10.1111/j.1349-7006.2010.01759.x. Epub 2010 Oct 21.
• [458] PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma.Neoplasia. 2018 Jan;20(1):12-24. doi: 10.1016/j.neo.2017.10.004. Epub 2017 Nov 23.
• [459] Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.Oncogene. 2018 Nov;37(46):6041-6053. doi: 10.1038/s41388-018-0403-0. Epub 2018 Jul 11.
• [460] MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy.J Surg Res. 2017 Dec;220:391-401. doi: 10.1016/j.jss.2017.07.003. Epub 2017 Sep 3.
• [461] Functional annotation of rare gene aberration drivers of pancreatic cancer.Nat Commun. 2016 Jan 25;7:10500. doi: 10.1038/ncomms10500.
• [462] Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1.Cell Death Dis. 2019 Dec 11;10(12):948. doi: 10.1038/s41419-019-2072-5.
• [463] Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.Cancer Res. 2017 May 15;77(10):2661-2673. doi: 10.1158/0008-5472.CAN-16-2339. Epub 2017 Mar 9.
• [464] Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.Clin Cancer Res. 2016 Dec 15;22(24):5992-6001. doi: 10.1158/1078-0432.CCR-16-0511. Epub 2016 Jul 8.
• [465] Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.Int J Cancer. 2016 Aug 1;139(3):628-38. doi: 10.1002/ijc.30110.
• [466] Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-B activity in pancreatic cancer cells.J Biol Chem. 2013 May 24;288(21):15121-30. doi: 10.1074/jbc.M113.470047. Epub 2013 Apr 16.
• [467] Loss of HNF6 expression correlates with human pancreatic cancer progression.Lab Invest. 2014 May;94(5):517-27. doi: 10.1038/labinvest.2014.47. Epub 2014 Mar 17.
• [468] 3D-spheroids: What can they tell us about pancreatic ductal adenocarcinoma cell phenotype?.Exp Cell Res. 2017 Aug 15;357(2):299-309. doi: 10.1016/j.yexcr.2017.05.027. Epub 2017 May 29.
• [469] The role of stromal cancer-associated fibroblasts in pancreatic cancer.J Hematol Oncol. 2017 Mar 28;10(1):76. doi: 10.1186/s13045-017-0448-5.
• [470] PARI overexpression promotes genomic instability and pancreatic tumorigenesis.Cancer Res. 2013 Apr 15;73(8):2529-39. doi: 10.1158/0008-5472.CAN-12-3313. Epub 2013 Feb 22.
• [471] Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1 axis.Mol Cancer. 2014 Aug 7;13:187. doi: 10.1186/1476-4598-13-187.
• [472] Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer.Pancreas. 2017 Jan;46(1):28-34. doi: 10.1097/MPA.0000000000000725.
• [473] PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.Cancer Res. 2016 Jan 1;76(1):96-107. doi: 10.1158/0008-5472.CAN-15-0216. Epub 2015 Dec 15.
• [474] Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin.Biomaterials. 2019 Feb;192:590-600. doi: 10.1016/j.biomaterials.2018.11.035. Epub 2018 Nov 30.
• [475] HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.Gut. 2009 Oct;58(10):1399-409. doi: 10.1136/gut.2009.180711. Epub 2009 Jun 14.
• [476] The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.Cancer Lett. 2013 Oct 1;339(1):135-43. doi: 10.1016/j.canlet.2013.07.010. Epub 2013 Jul 22.
• [477] Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1336-43. doi: 10.1158/1055-9965.EPI-12-0223. Epub 2012 Jun 4.
• [478] The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.Mol Cancer. 2015 Jul 29;14:139. doi: 10.1186/s12943-015-0412-3.
• [479] PRDM14 is overexpressed in chronic pancreatitis prior to pancreatic cancer.FEBS Open Bio. 2018 Sep 17;8(10):1733-1741. doi: 10.1002/2211-5463.12519. eCollection 2018 Oct.
• [480] Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells.BMC Cancer. 2019 Mar 21;19(1):253. doi: 10.1186/s12885-019-5455-1.
• [481] MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma.Sci Rep. 2016 Mar 15;6:22793. doi: 10.1038/srep22793.
• [482] Inactivation of Rab23 inhibits the invasion and motility of pancreatic duct adenocarcinoma.Genet Mol Res. 2015 Mar 30;14(1):2707-15. doi: 10.4238/2015.March.30.31.
• [483] SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer.J Cancer. 2019 Jun 2;10(12):2670-2678. doi: 10.7150/jca.32072. eCollection 2019.
• [484] Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis.Int J Biol Sci. 2018 Jan 12;14(2):124-136. doi: 10.7150/ijbs.22619. eCollection 2018.
• [485] Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.Oncotarget. 2016 Nov 22;7(47):77838-77853. doi: 10.18632/oncotarget.12834.
• [486] Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.J Biol Chem. 2010 Nov 5;285(45):34729-40. doi: 10.1074/jbc.M110.116756. Epub 2010 Aug 27.
• [487] Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Biochim Biophys Acta. 2015 Jan;1853(1):89-100. doi: 10.1016/j.bbamcr.2014.10.003. Epub 2014 Oct 13.
• [488] ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF- signalling.Nat Commun. 2018 Nov 30;9(1):5083. doi: 10.1038/s41467-018-07497-z.
• [489] Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.Mol Med Rep. 2018 Jan;17(1):216-224. doi: 10.3892/mmr.2017.7850. Epub 2017 Oct 20.
• [490] Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation.Br J Cancer. 2007 Jan 29;96(2):373-82. doi: 10.1038/sj.bjc.6603563.
• [491] SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment.Transl Oncol. 2019 Jan;12(1):15-23. doi: 10.1016/j.tranon.2018.08.019. Epub 2018 Sep 20.
• [492] Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.Pancreas. 2019 Mar;48(3):315-322. doi: 10.1097/MPA.0000000000001253.
• [493] Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression.J Clin Invest. 2014 May;124(5):2125-35. doi: 10.1172/JCI72619. Epub 2014 Apr 1.
• [494] Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-1/smad2/3 axis in pancreatic cancer.Cancer Lett. 2019 Sep 10;459:204-215. doi: 10.1016/j.canlet.2019.06.005. Epub 2019 Jun 12.
• [495] SMDT1-driven change in mitochondrial dynamics mediate cell apoptosis in PDAC.Biochem Biophys Res Commun. 2019 Apr 2;511(2):323-329. doi: 10.1016/j.bbrc.2019.02.043. Epub 2019 Feb 16.
• [496] Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.Neoplasia. 2007 Jan;9(1):8-17. doi: 10.1593/neo.06646.
• [497] Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the -catenin/TCF4 pathway through SPRY2.J Exp Clin Cancer Res. 2019 Jan 28;38(1):38. doi: 10.1186/s13046-019-1046-x.
• [498] ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.J Biol Chem. 2018 Jan 19;293(3):984-994. doi: 10.1074/jbc.M117.808584. Epub 2017 Nov 30.
• [499] Identification of a novel alternative splicing transcript variant of the suppressor of fused: Relationship with lymph node metastasis in pancreatic ductal adenocarcinoma.Int J Oncol. 2016 Dec;49(6):2611-2619. doi: 10.3892/ijo.2016.3753. Epub 2016 Nov 3.
• [500] Personalized RNA Medicine for Pancreatic Cancer.Clin Cancer Res. 2018 Apr 1;24(7):1734-1747. doi: 10.1158/1078-0432.CCR-17-2733. Epub 2018 Jan 12.
• [501] Identification of potential biomarkers to differentially diagnose solid pseudopapillary tumors and pancreatic malignancies via a gene regulatory network.J Transl Med. 2015 Nov 14;13:361. doi: 10.1186/s12967-015-0718-3.
• [502] Transforming growth factor beta-induced, an extracellular matrix interacting protein, enhances glycolysis and promotes pancreatic cancer cell migration.Int J Cancer. 2019 Sep 15;145(6):1570-1584. doi: 10.1002/ijc.32247. Epub 2019 Mar 28.
• [503] A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.Theranostics. 2019 Feb 12;9(5):1280-1287. doi: 10.7150/thno.29247. eCollection 2019.
• [504] CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.Cancer Lett. 2019 Jul 1;453:158-169. doi: 10.1016/j.canlet.2019.03.051. Epub 2019 Apr 4.
• [505] TM4SF18 is aberrantly expressed in pancreatic cancer and regulates cell growth.PLoS One. 2019 Mar 21;14(3):e0211711. doi: 10.1371/journal.pone.0211711. eCollection 2019.
• [506] Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.Oncotarget. 2016 Apr 26;7(17):23263-81. doi: 10.18632/oncotarget.8139.
• [507] Collagen Complexity Spatially Defines Microregions of Total Tissue Pressure in Pancreatic Cancer.Sci Rep. 2017 Aug 30;7(1):10093. doi: 10.1038/s41598-017-10671-w.
• [508] Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma.Front Genet. 2018 Apr 5;9:108. doi: 10.3389/fgene.2018.00108. eCollection 2018.
• [509] Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma.Oncogene. 2020 Jan;39(2):308-321. doi: 10.1038/s41388-019-0985-1. Epub 2019 Sep 2.
• [510] CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-B signaling.Oncogene. 2015 Jan 8;34(2):177-87. doi: 10.1038/onc.2013.530. Epub 2013 Dec 16.
• [511] Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.J Exp Med. 2019 Mar 4;216(3):656-673. doi: 10.1084/jem.20180749. Epub 2019 Feb 7.
• [512] FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.J Cell Biochem. 2020 Mar;121(3):2458-2466. doi: 10.1002/jcb.29468. Epub 2019 Nov 6.
• [513] Kindlin-2 in pancreatic stellate cells promotes the progression of pancreatic cancer.Cancer Lett. 2017 Apr 1;390:103-114. doi: 10.1016/j.canlet.2017.01.008. Epub 2017 Jan 16.
• [514] Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma.Oncogene. 2019 Jun;38(26):5308-5320. doi: 10.1038/s41388-019-0794-6. Epub 2019 Mar 27.
• [515] GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.FASEB J. 2018 Mar;32(3):1170-1183. doi: 10.1096/fj.201700834R. Epub 2018 Jan 3.
• [516] KAT2A succinyltransferase activity-mediated 14-3-3 upregulation promotes -catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells.Cancer Lett. 2020 Jan 28;469:1-10. doi: 10.1016/j.canlet.2019.09.015. Epub 2019 Oct 11.
• [517] Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC.Biochem Biophys Res Commun. 2018 May 15;499(3):584-593. doi: 10.1016/j.bbrc.2018.03.194. Epub 2018 Apr 4.
• [518] HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.Pathol Res Pract. 2019 Feb;215(2):343-346. doi: 10.1016/j.prp.2018.12.016. Epub 2018 Dec 12.
• [519] LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation.Clin Cancer Res. 2019 Jul 1;25(13):4091-4103. doi: 10.1158/1078-0432.CCR-18-3533. Epub 2019 Jan 24.
• [520] TGF- induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.Nat Commun. 2018 May 10;9(1):1845. doi: 10.1038/s41467-018-03962-x.
• [521] Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma.Hum Pathol. 2019 Apr;86:143-154. doi: 10.1016/j.humpath.2018.11.026. Epub 2018 Dec 9.
• [522] Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma.PLoS One. 2018 Dec 7;13(12):e0208557. doi: 10.1371/journal.pone.0208557. eCollection 2018.
• [523] MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.Cell Death Dis. 2019 Feb 27;10(3):206. doi: 10.1038/s41419-019-1424-5.
• [524] miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.Oncogene. 2015 Feb 5;34(6):780-8. doi: 10.1038/onc.2014.11. Epub 2014 Mar 10.
• [525] Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity through the Control of Oxidative Phosphorylation.Cancers (Basel). 2019 Jun 19;11(6):853. doi: 10.3390/cancers11060853.
• [526] Aberrant NFATc1 signaling counteracts TGF-mediated growth arrest and apoptosis induction in pancreatic cancer progression.Cell Death Dis. 2019 Jun 6;10(6):446. doi: 10.1038/s41419-019-1682-2.
• [527] Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.EBioMedicine. 2019 Feb;40:394-405. doi: 10.1016/j.ebiom.2019.01.037. Epub 2019 Jan 30.
• [528] Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.
• [529] Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes.Surg Oncol. 2018 Dec;27(4):619-624. doi: 10.1016/j.suronc.2018.07.014. Epub 2018 Aug 3.
• [530] Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.Gut. 2020 May;69(5):888-900. doi: 10.1136/gutjnl-2018-317163. Epub 2019 Oct 14.
• [531] Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis.Pancreatology. 2019 Apr;19(3):443-448. doi: 10.1016/j.pan.2019.03.001. Epub 2019 Mar 11.
• [532] POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma.Oncotarget. 2019 Feb 22;10(16):1572-1588. doi: 10.18632/oncotarget.26705. eCollection 2019 Feb 22.
• [533] Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma.Lab Invest. 2015 Jan;95(1):43-55. doi: 10.1038/labinvest.2014.128. Epub 2014 Oct 27.
• [534] PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.Oncogene. 2019 May;38(22):4325-4339. doi: 10.1038/s41388-019-0725-6. Epub 2019 Jan 31.
• [535] NO(? /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.Int J Cancer. 2020 Jun 1;146(11):3160-3169. doi: 10.1002/ijc.32733. Epub 2019 Nov 19.
• [536] First implication of STRA6 mutations in isolated anophthalmia, microphthalmia, and coloboma: a new dimension to the STRA6 phenotype. Hum Mutat. 2011 Dec;32(12):1417-26. doi: 10.1002/humu.21590. Epub 2011 Sep 29.
• [537] Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival.Sci Rep. 2018 Sep 13;8(1):13759. doi: 10.1038/s41598-018-32034-9.
• [538] Downregulation of thymopoietin by miR-139-5p suppresses cell proliferation and induces cell cycle arrest/apoptosis in pancreatic ductal adenocarcinoma.Oncol Lett. 2019 Oct;18(4):3443-3452. doi: 10.3892/ol.2019.10679. Epub 2019 Jul 29.